Macrocyclic compound and use thereof

By developing a macrocyclic compound to form a ternary complex with CypA, the RAS-RAF-MEK-ERK signaling pathway is blocked, solving the problem of the lack of targeted Ras protein therapy in existing technologies, and achieving effective inhibition of Ras protein mutations and cancer treatment effects.

WO2026233431A1PCT designated stage Publication Date: 2026-11-12WIGEN BIOMEDICINE TECH (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095667
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-02-03
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There are currently no effective treatments targeting the Ras protein, especially for patients with non-G12C Ras protein mutations and overactivation of the Ras pathway, leaving a gap in clinical treatment options.

Method used

A class of macrocyclic compounds was developed that can block the RAS-RAF-MEK-ERK signaling pathway and inhibit the activity of RAS protein by forming a ternary complex with the in vivo molecular chaperone protein CypA.

Benefits of technology

It achieves effective inhibition of Ras protein mutations, with good survival and disease control effects, and is suitable for the treatment of various cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095667_12112026_PF_FP_ABST
    Figure CN2026095667_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a macrocyclic compound and a use thereof. Specifically, the present invention relates to a compound represented by general formula (1) and a preparation method therefor, and a use of the compound of general formula (1) and various isomers, various crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof as RAS inhibitors in the preparation of antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Macrocyclic compounds and their uses

[0001] This application claims priority to Chinese patent applications 202510590239.7, filed May 8, 2025; 202510917602.1, filed July 3, 2025; 202511410007.5, filed September 29, 2025; and 202610153305.9, filed February 3, 2026. The full text of the aforementioned Chinese patent applications is incorporated herein by reference. Technical Field

[0002] This invention belongs to the field of medicinal chemistry, and more specifically, relates to a class of macrocyclic compounds, their preparation methods, and their application in the preparation of drugs for treating or preventing cancer. Background Technology

[0003] Overactivation of Ras family proteins is a significant contributing factor to the development and progression of various cancers. Targeting and inhibiting Ras protein activity is an important approach in cancer treatment.

[0004] Ras protein exists in two forms: bound to GDP and bound to GTP. When bound to GDP, it remains in an inactive, quiescent state. Upon binding to GTP, Ras protein is activated, recruiting various signal transduction proteins and promoting the phosphorylation of downstream signaling molecules such as ERK and S6, thus activating the Ras signaling pathway and regulating cell growth, survival, migration, and differentiation. Ras protein's own GTPase activity can hydrolyze GTP back to GDP. The interaction between GTPase-activating proteins (GAPs) and Ras significantly promotes Ras GTPase activity, thereby preventing overactivation of the Ras protein.

[0005] Mutations in the K-Ras, H-Ras, and N-Ras proteins of the Ras protein family lead to overactivation of Ras proteins in tumors and are among the most common gene mutations in tumors. Compared to wild-type Ras proteins, these mutations result in more active Ras proteins that stably bind to GTP and remain continuously activated. Mutations in the K-Ras protein are the most common, accounting for 85% of all Ras mutations, while N-Ras (12%) and H-Ras (3%) are relatively rare. K-Ras mutations are extremely prevalent in various cancers, including pancreatic cancer (95%), colorectal cancer (45%), lung cancer (25%), and ovarian cancer (9%). K-Ras mutation sites are mainly concentrated at the G12 position, including mutations in G12D / V / C / A / S / R. Besides tumors, abnormal activation of Ras protein is also involved in non-tumor diseases, including diabetes and neurodegenerative diseases. Therefore, small molecule compounds targeting Ras protein can benefit a large number of cancer patients carrying specific gene mutations and non-cancer patients with over-activation of the Ras pathway.

[0006] Forty years since Ras mutations were discovered in tumors, although our understanding of the pathogenic mechanism of the Ras pathway has deepened and the development of G12C-targeted inhibitors has brought hope to some patients, there are still no effective Ras-targeting therapies available clinically for the large number of patients carrying non-G12C Ras protein mutations and those with overactivated Ras pathways. Therefore, developing highly active small-molecule inhibitors targeting mutant Ras proteins is of significant clinical importance.

[0007] Research on Pan RAS inhibitors targeting multiple G12 mutations is still limited, with only a few compounds having entered clinical trials. Revolution Medicines, Inc. recently disclosed a class of macrocyclic compounds that can form a ternary complex with the molecular chaperone proteins CypA and RAS(on) in vivo, blocking the binding of RAS to downstream RAF, thereby inhibiting the RAS-RAF-MEK-ERK signaling pathway and achieving an anti-tumor effect. A representative compound, RMC-6236, achieved very good survival and disease control effects in a Phase I clinical trial for PDAC. There is an urgent need to design and optimize this type of compound, researching and discovering compounds with good activity and excellent pharmacokinetic properties. Summary of the Invention

[0008] This invention provides a compound of general formula (1) or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates:

[0009] In general formula (1):

[0010] Ring D is (C5-C14) heterocyclic alkyl, (C6-C14) aryl, or (5-14) heteroaryl;

[0011] X1 and X2 are each independently N or CR d ;

[0012] X3 is CR 5 or NR 5 X4 is either C or N, and X3 and X4 are not both N at the same time;

[0013] Indicates a single or double bond, and when X3 or X4 is N, the bond connected to it is... Represented as a single bond;

[0014] R 1 For -OR a -NR a R b (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace;

[0015] R 2 Each can be independently represented as -H, -D, halogen, hydroxyl, amino, cyano, nitro, or -OR. a -NR a R b -C(O)R a -CO2R a -S(O) p R a -S(O) p NR a R b -C(O)NR a R b -C(=NR) a )-NR b R c -NR a C(O)R b -NR a C(O)NR b R c -NR aCO2R b -NR a S(O) p NR b R c -NR a S(O) p R b -P(O)R a R b -P(S)R a R b -N(=S(O)R a R b ), -BR a R b (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace;

[0016] R 3 -H, -D, halogen, hydroxyl, amino, cyano, nitro, -OR a -NR a R b -C(O)R a -CO2R a -S(O) p R a -S(O) p NR a R b -C(O)NR a R b -C(=NR) a )-NR b R c -NR a C(O)R b -NR a C(O)NR b R c -NR a CO2R b -NR a S(O) p NR b R c -NRa S(O) p R b -P(O)R a R b -P(S)R a R b -N(=S(O)R a R b ), -BR a R b (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace;

[0017] R 5 The radical is -H, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently optionally surrounded by 1, 2, 3, or 4 R radicals. d replace;

[0018] R 6 The radical is -H, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently optionally surrounded by 1, 2, 3, or 4 R radicals. d replace;

[0019] R7 The alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or 5-14 heteroaryl groups are (C1-C8)alkyl, (C1-C8)alkoxy, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or 5-14 heteroaryl groups, wherein each of the (C1-C8)alkyl, (C1-C8)alkoxy, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or 5-14 heteroaryl groups may be independently optionally surrounded by 1, 2, 3, or 4 R groups. d replace;

[0020] Or R 5 With R 7 The atoms attached to the alkyl group together constitute a (7-16 member) heterocyclic alkyl group, wherein each heterocyclic alkyl group may be independently optionally bound by 1, 2, 3 or 4 R groups. d replace;

[0021] R 4 -H, -D, halogen, hydroxyl, amino, cyano, nitro, -OR a -NR a R b -C(O)R a -CO2R a -S(O) p R a -S(O) p NR a R b -C(O)NR a R b -C(=NR) a )-NR b R c -NR a C(O)R b -NR a C(O)NR b R c -NR a CO2R b -NR a S(O) p NR b R c -NR a S(O) p R b -P(O)R a R b -P(S)R a R b -N(=S(O)R aR b ), -BR a R b (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace;

[0022] R a R b and R c Each of these components is independently H, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl, or -(C1-C8)alkylene-(5-14-membered)heteroaryl, wherein (C 1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3 or 4 Rs. e replace;

[0023] Or R a and R b R b and R c or R a and R c Together with one or more atoms to which they are attached, they form (3-12-membered) heterocyclic alkyl groups, wherein the (3-12-membered) heterocyclic alkyl groups may optionally be composed of 1, 2, 3 or 4 R atoms. e replace;

[0024] Rd Each can be independently represented as -H, -D, halogen, hydroxyl, amino, cyano, nitro, or -OR. e -NR e R f -NR e NR f R g -NR e OR f -OR e NR f -C(O)R e -CO2R e -S(O) p R e -S(O) p NR e R f -C(O)NR e R f -C(=NR) e )-NR f R g -NR e C(O)R f -NR e C(O)NR f R g -NR e CO2R f -NR e S(O) p NR f R g -NR e S(O) p R f -P(O)R e R f -P(S)R e R f -N(=S(O)R e R f(C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C2-C8)alkynyl-(C1-C8)alkylene, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl or -(C1-C8)alkylene-(5-14-membered)heteroaryl The (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl, and -(C1-C8)alkylene-(5-14-membered)heteroaryl groups may each be independently optionally surrounded by 1, 2, 3, or 4 R groups. e replace;

[0025] Or when 2 R d When attached to the same atom, an oxo group can be formed or a (C3-C8) cycloalkyl or (3-8) heterocycloalkyl group can be formed with the attached atom. The (C3-C8) cycloalkyl or (3-8) heterocycloalkyl group can be independently and optionally attached to 1, 2, 3 or 4 R groups. e replace;

[0026] R e Each can be independently represented as -H, -D, halogen, hydroxyl, amino, cyano, nitro, or -OR. f -NR f R g -NR f NR g R h -NR f OR g -OR f NR g -C(O)R f -CO2R f -S(O) p R f -S(O) p NR f R g -C(O)NR f R g -C(=NR) f )-NRf R h -NR f C(O)R g -NR f C(O)NR g R h -NR f CO2R g -NR f S(O) p NR g R h -NR f S(O) p R g (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl or -(C1-C8)alkylene-(5-14-membered)heteroaryl, wherein the (C1-C8)alkyl The following groups can be independently and optionally substituted with 1, 2, 3 or 4 Rs: alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl.

[0027] R f R g and R hEach of these components is independently H, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl, or -(C1-C8)alkylene-(5-14-membered)heteroaryl, wherein (C1-C8)... 8) Alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl can each be independently and optionally substituted with 1, 2, 3 or 4 Rs;

[0028] R can be -H, -D, halogen, hydroxyl, amino, cyano, nitro, -NH-NH2, -ONH2, -NHOH, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocyclic alkyl, -(C1-C8)alkylene-(C6-C14)aryl, or -(C1-C8)alkylene-(5-14-membered)heteroaryl.

[0029] n and p are integers of 0, 1, 2, 3 or 4 respectively.

[0030] In another preferred embodiment, in the general formula (1), R 1 It is a (C3-C10) cycloalkyl or a (3-10) heterocycloalkyl, wherein each of the (C3-C10) cycloalkyl or (3-10) heterocycloalkyl is independently and optionally substituted with 1, 2, 3 or 4 H, D, methyl, halomethyl or deuterated methyl.

[0031] In another preferred embodiment, in the general formula (1), R 1It is a (C3-C7) cycloalkyl or a (4-7) heterocycloalkyl, wherein each of the (C3-C7) cycloalkyl or (4-7) heterocycloalkyl is independently and optionally substituted with 1, 2, 3 or 4 H, D, methyl, halomethyl or deuterated methyl.

[0032] In another preferred embodiment, in the general formula (1), X1 and X2 are each independently N or CR. d R d X1 is -H, -D, or a halogen; X1 is preferably CH, CF, or N; X2 is preferably CH; X3 is CR. 5 or NR 5 X4 is either C or N, and X3 and X4 are not both N at the same time.

[0033] In another preferred embodiment, in the general formula (1), R 3 -H, -D, halogen, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C4)alkenyl, (C2-C4)ynyl, or (C3-C6)cycloalkyl; R 3 Preferably, it is -H, -D, halogen, methyl or -CF3.

[0034] In another preferred embodiment, in the general formula (1), the structural unit for Preferred

[0035] In another preferred embodiment, in the general formula (1), R 5 The radical is -H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)ynyl, (C3-C10)cycloalkyl, (3-10-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)ynyl, (C3-C10)cycloalkyl, (3-10-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently optionally surrounded by 1, 2, 3, or 4 R radicals. d Replace; R 5 Preferably, they are (C2-C4)alkyl, (C2-C4)alkoxy, (C2-C4)haloalkyl, (C3-C5)cycloalkyl, or (3-5)heterocyclic alkyl, wherein the (C2-C4)alkyl, (C2-C4)alkoxy, (C2-C4)haloalkyl, (C3-C5)cycloalkyl, and (3-5)heterocyclic alkyl groups may each be independently optionally surrounded by 1, 2, 3, or 4 R groups. d Replace; R 5 Further preferred

[0036] In another preferred embodiment, in the general formula (1), R 2 -H, -D, halogen, hydroxyl, amino, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C4)alkenyl, (C2-C4)ynyl, or (C3-C6)cycloalkyl; R 2 Preferably, it is -H, -D, halogen, methyl, hydroxyl or amino.

[0037] In another preferred embodiment, wherein in the general formula (1), ring D is a (C5-C6) heterocyclic alkyl, phenyl, or (5-6-membered) heteroaryl; ring D is preferably... Ring D is more preferably The asterisk (*) indicates that it is connected to an aromatic ring.

[0038] In another preferred embodiment, in the general formula (1), R 4 For -OR a -NR a R b P(O)R a R b -P(S)R a R b -N(=S(O)R a R b (C2-C4) ynyl, (C3-C10) cycloalkyl, or (3-10) heterocyclic alkyl, wherein the (C2-C4) ynyl, (C3-C10) cycloalkyl, or (3-10) heterocyclic alkyl can each be independently and optionally surrounded by 1, 2, 3, or 4 R groups. d replace.

[0039] In another preferred embodiment, in the general formula (1), R 4 It is (C2-C3) ynyl, (5-10) heterocyclic alkyl, phenyl, or (5-7) heteroaryl, wherein the (C2-C3) ynyl, (5-10) heterocyclic alkyl, phenyl, or (5-7) heteroaryl can each be independently optionally surrounded by 1, 2, 3, or 4 R groups. d replace.

[0040] In another preferred embodiment, in the general formula (1), R 4 It is a propynyl, a 6-membered heterocyclic alkyl, a phenyl, or a 5-membered heteroaryl, wherein the propynyl, 6-membered heterocyclic alkyl, phenyl, or 5-membered heteroaryl group can each be independently selected with -NR. e R f -C(O)R eThe alkyl group is substituted with (C1-C3)alkyl or (3-6)heterocyclic alkyl, wherein the (C1-C3)alkyl or (3-6)heterocyclic alkyl group may be independently and optionally substituted with 1, 2, 3 or 4 R groups. e replace.

[0041] In another preferred embodiment, in the general formula (1), R a R b and R c Each of these components is independently H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (3-10-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C6)alkylene-(C3-C10)cycloalkyl, -(C1-C6)alkylene-(3-10-membered)heterocyclic alkyl, -(C1-C6)alkylene-(C6-C14)aryl, or -(C1-C6)alkylene-(5-14-membered)heteroaryl, wherein (C 1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (3-10-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C6)alkylene-(C3-C10)cycloalkyl, -(C1-C6)alkylene-(3-10-membered)heterocyclic alkyl, -(C1-C6)alkylene-(C6-C14)aryl, -(C1-C6)alkylene-(5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3 or 4 Rs. e Replace; or R a and R b R b and R c or R a and R c Together with one or more atoms to which they are attached, they form (3-12-membered) heterocyclic alkyl groups, wherein the (3-12-membered) heterocyclic alkyl groups may optionally be composed of 1, 2, 3 or 4 R atoms. e Replace; R a R b Preferably, the alkyl group is H, D, (C1-C4)alkyl, (C1-C4)alkoxy, or (3-10)heterocyclic alkyl, wherein the (C1-C4)alkyl, (C1-C4)alkoxy, or (3-10)heterocyclic alkyl group may each be independently and optionally surrounded by 1, 2, 3, or 4 R groups. e Replace; or R a and R b Together with one or more atoms to which they are attached, they form (3-12-membered) heterocyclic alkyl groups, wherein the (3-12-membered) heterocyclic alkyl groups may optionally be composed of 1, 2, 3 or 4 R atoms.e replace.

[0042] In another preferred embodiment, in the general formula (1), R 6 The radical is -H, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)ynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently optionally surrounded by 1, 2, 3, or 4 R radicals. d Replace; R 6 Preferably (C1-C4)alkyl or (C1-C4)alkoxy; R 6 Methyl, ethyl or methoxyethyl are preferred.

[0043] In another preferred embodiment, in the general formula (1), R 7 The alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or 5-14 heteroaryl groups are (C1-C8)alkyl, (C1-C8)alkoxy, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or 5-14 heteroaryl groups, wherein each of the (C1-C8)alkyl, (C1-C8)alkoxy, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, or 5-14 heteroaryl groups may be independently optionally surrounded by 1, 2, 3, or 4 R groups. d Replace; R 7 Preferably (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C3-C6)cycloalkyl, or (3-8)heterocyclic alkyl, wherein the (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)haloalkyl, (C3-C6)cycloalkyl, or (3-8)heterocyclic alkyl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d Replace; R 7 Methyl, ethyl or methoxyethyl are preferred.

[0044] In another preferred embodiment, in the general formula (1), R 5 With R 7 The atoms attached to the alkyl group together constitute a (7-16 member) heterocyclic alkyl group, wherein each heterocyclic alkyl group may be independently optionally bound by 1, 2, 3 or 4 R groups. d Replace; R5 With R 7 The atoms to which it is attached are preferably (8-12 member) heterocyclic alkyl groups, each of which may be independently optionally bound by 1, 2, 3 or 4 R groups. d replace.

[0045] In another preferred embodiment, in the general formula (1), R e Each can be independently represented as -H, -D, halogen, hydroxyl, amino, cyano, nitro, or -OR. f -NR f R g -NR f NR g R h -NR f OR g -OR f NR g -C(O)R f -CO2R f -S(O) p R f -S(O) p NR f R g -C(O)NR f R g -C(=NR) f )-NR f R h -NR f C(O)R g -NR f C(O)NR g R h -NR f CO2R g -NR f S(O) p NR g R h -NR f S(O) p R g(C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (4-7-membered)heterocyclic alkyl, phenyl, (5-6-membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6-membered)heterocyclic alkyl, -(C1-C2)alkylene-phenyl or -(C1-C2)alkylene-(5-6-membered)heteroaryl, wherein the (C1-C3)alkyl (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (4-7-membered)heterocyclic alkyl, phenyl, (5-6-membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6-membered)heterocyclic alkyl, -(C1-C2)alkylene-phenyl, -(C1-C2)alkylene-(5-6-membered)heteroaryl, each of which can be independently and optionally substituted with 1, 2, 3 or 4 Rs.

[0046] In another preferred embodiment, in the general formula (1), R f R g and R h Each of the following is independently H, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (3-6-membered)heterocyclic alkyl, (C6-C10)aryl, (5-6-membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6-membered)heterocyclic alkyl, -(C1-C2)alkylene-(C6-C10)aryl or -(C1-C2)alkylene-(5-6-membered)heteroaryl, wherein (C1-C 3) Alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (3-6-membered)heterocyclic alkyl, (C6-C10)aryl, (5-6-membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6-membered)heterocyclic alkyl, -(C1-C2)alkylene-(C6-C10)aryl, -(C1-C2)alkylene-(5-6-membered)heteroaryl can each be independently and optionally substituted with 1, 2, 3 or 4 Rs.

[0047] In another preferred embodiment, in the general formula (1), R is independently -H, -D, halogen, hydroxyl, amino, cyano, nitro, -NH-NH2, -ONH2, -NHOH, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (3-6-membered)heterocyclic alkyl, phenyl, (5-6-membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6-membered)heterocyclic alkyl, -(C1-C2)alkylene-(C6-C10)aryl or -(C1-C2)alkylene-(5-6-membered)heteroaryl.

[0048] In another preferred embodiment, wherein the compound of general formula (1) has one of the following structures:

[0049] Another object of the present invention is to provide a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a diluent and / or an excipient, and a compound of the general formula of the present invention, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as active ingredients.

[0050] Another object of the present invention is to provide the use of the compounds of the general formula of the present invention, or their isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, or the pharmaceutical compositions thereof, in the preparation of medicaments for the treatment, regulation or prevention of diseases related to RAS protein kinase.

[0051] Another object of the present invention is to provide a method for treating, modulating or preventing diseases associated with RAS protein kinase, comprising administering to a subject a therapeutically effective amount of a compound of the general formula of the present invention, or any isomer thereof, crystal form thereof, pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof.

[0052] It should be understood that the foregoing general description of the invention and the following detailed description are exemplary and illustrative, and are intended to provide further explanation of the claimed invention.

[0053] Compound Synthesis

[0054] The preparation method of the compound of general formula (1) of the present invention is described in detail below, but these specific methods do not constitute any limitation on the present invention.

[0055] The compounds of general formula (1) described above can be synthesized using standard synthetic techniques or known techniques combined with the methods described herein. Furthermore, the solvents, temperatures, and other reaction conditions mentioned herein can be varied. Starting materials used in the synthesis of the compounds can be obtained synthetically or from commercial sources. The compounds described herein and other related compounds with different substituents can be synthesized using known techniques and starting materials, including those discovered in March, ADVANCED ORGANIC CHEMISTRY 4. th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4 th Ed., Vols.A and B (Plenum 2000, 2001), Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 rd The method described in Ed. (Wiley 1999) can be used to prepare compounds by employing appropriate reagents and by introducing different groups into the molecular formulas provided herein.

[0056] On the one hand, the compounds described herein are prepared according to methods known in the art. However, the conditions of the method, such as reactants, solvents, bases, amounts of compounds used, reaction temperatures, and reaction times, are not limited to those explained below. The compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, such combinations being readily performed by those skilled in the art.

[0057] Further forms of the compound

[0058] "Pharmaceutical acceptable" here means that a substance, such as a carrier or diluent, will not destroy the biological activity or properties of a compound and is relatively non-toxic. For example, when given to an individual, a substance will not cause unwanted biological effects or interact with any of its components in a harmful manner.

[0059] The term "pharmaceutically acceptable salt" refers to a form of a compound that does not cause significant irritation to the administered organism and does not diminish the compound's biological activity and properties. In some specific aspects, pharmaceutically acceptable salts are obtained by reacting a compound of a general formula with an acid or base, wherein said acid or base includes, but is not limited to, those found in Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use 1. st Acids and bases in Ed. (Wiley, 2002).

[0060] It should be understood that references to pharmaceutically acceptable salts include solvent-added forms or crystalline forms, especially solvates or polymorphs. Solvates contain stoichiometric or non-stoichiometric solvents and are selectively formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. A hydrate is formed when the solvent is water, or an alcohol is formed when the solvent is ethanol. Solvates of compounds of general formula (1) are readily prepared or formed according to the methods described herein. For example, hydrates of compounds of general formula (1) are readily prepared by recrystallization from a mixture of water and organic solvents, including but not limited to tetrahydrofuran, acetone, ethanol, or methanol. Furthermore, the compounds mentioned herein can exist in both solvated and non-solvated forms. In summary, for the purposes of the compounds and methods provided herein, the solvated form is considered equivalent to the non-solvated form.

[0061] In other specific embodiments, compounds of general formula (1) are prepared in various forms, including but not limited to amorphous, pulverized, and nano-particle forms. Furthermore, compounds of general formula (1) include crystalline forms and can also be polymorphic. Polymorphs comprise different lattice arrangements of the same elemental composition of the compound. Polymorphs typically have different X-ray diffraction spectra, infrared spectra, melting points, densities, hardness, crystal forms, optical and electrical properties, stability, and solubility. Different factors such as recrystallization solvents, crystallization rates, and storage temperatures may cause a single crystal form to dominate.

[0062] In another aspect, compounds of general formula (1) may possess a chiral center and / or axial chirality, and thus appear as racemates, racemic mixtures, single enantiomers, diastereomers, and single diastereomers, and cis-trans isomers. Each chiral center or axial chirality will independently produce two optical isomers, and all possible optical isomers and diastereomer mixtures, as well as pure or partially pure compounds, are included within the scope of this invention. This invention means including all such isomeric forms of these compounds.

[0063] The compounds of this invention may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium. 3 H), Oxygen-18 ( 18 O), Iodine-125 ( 125 I) and C-14 14 C). For example, deuterium can be used to replace hydrogen atoms to form deuterated compounds. The bond between deuterium and carbon is stronger than that between ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs generally have advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged drug half-life in vivo. All isotopic variations of the compounds of this invention, regardless of radioactivity, are included within the scope of this invention.

[0064] Unless otherwise specified, any atom in the compounds described in this invention refers to its stable-state isotope. Unless otherwise specified, when a site on the molecular structure is chosen as "H" or "hydrogen", that site should be understood as having a natural abundance of hydrogen isotopes. Similarly, unless otherwise specified, when a site is chosen as "D" or "deuterium", that site should be understood as having a deuterium isotope abundance of at least 3000 times its natural abundance (the natural abundance of deuterium isotopes is 0.015%).

[0065] More preferably, the deuterium abundance at each deuteration site of the deuterated compound in this invention is at least 3500 times its natural abundance (52.2% deuterium enrichment). More preferably, at least 4500 times (67.5% deuterium enrichment). More preferably, at least 5000 times (75% deuterium enrichment). More preferably, at least 6000 times (90% deuterium enrichment). More preferably, at least 6333 times (95% deuterium enrichment). More preferably, at least 6466.7 times (97% deuterium enrichment). More preferably, at least 6600 times (99% deuterium enrichment). More preferably, at least 6633.3 times (99.5% deuterium enrichment).

[0066] the term

[0067] Unless otherwise specified, the terms used in this application, including the specification and claims, are defined as follows. It must be noted that in the specification and appended claims, unless otherwise clearly indicated, the singular form "a" includes the plural meaning. Unless otherwise specified, substituents (such as alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.) in this application are optionally substituted, i.e., they can be substituted or unsubstituted. Unless otherwise specified, conventional methods such as mass spectrometry, nuclear magnetic resonance, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology are used. In this application, unless otherwise specified, "or" or "and" refers to "and / or".

[0068] Unless otherwise specified, "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight-chain and branched groups with 1 to 6 carbon atoms. Lower alkyl groups containing 1 to 4 carbon atoms are preferred, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, and tert-butyl. Lower alkyl groups containing 1 to 3 carbon atoms are more preferred, such as methyl, ethyl, propyl, and 2-propyl. As used herein, "alkyl" includes unsubstituted and substituted alkyl groups, especially alkyl groups substituted with one or more halogens. Preferred alkyl groups are selected from CH3, CH3CH2, CF3, CHF2, CF3CH2, CF3(CH3)CH, etc. i Pr、 n Pr、 i Bu、 n Bu or t Bu.

[0069] Unless otherwise specified, "alkylene" means a divalent alkyl group as defined above. Examples of alkylene include, but are not limited to, methylene and ethylene.

[0070] Unless otherwise specified, "alkenyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon double bond, including straight-chain or branched groups with 1 to 14 carbon atoms. Lower alkenyl groups containing 1 to 4 carbon atoms are preferred, such as vinyl, 1-propenyl, 1-butenyl, or 2-methylpropenyl. Lower alkenyl groups containing 1 to 2 carbon atoms are more preferred.

[0071] Unless otherwise specified, “alkenyl” refers to a divalent alkenyl group as defined above.

[0072] Unless otherwise specified, "alkynyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon triple bond, including straight-chain and branched groups with 1 to 14 carbon atoms. Lower alkynyl groups containing 1 to 4 carbon atoms are preferred, such as ethynyl, 1-propynyl, or 1-butynyl. Lower alkynyl groups containing 1 to 2 carbon atoms are more preferred.

[0073] Unless otherwise specified, “ethynyl” means a divalent ethynyl group as defined above.

[0074] Unless otherwise specified, "cycloalkyl" refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic, or polycyclic), preferably containing 3-14 ring carbon atoms (C14-C24). 3-14 A non-aromatic hydrocarbon ring system (cycloalkyl). In some embodiments, the cycloalkyl group has 3-10 ring carbon atoms (C60-C70). 3-10 (Cycloalkyl). In some embodiments, the cycloalkyl group has 3-8 cyclic carbon atoms (C60-C85). 3-8 (Cycloalkyl). In some embodiments, the cycloalkyl group has 3-7 cyclic carbon atoms (C60-C75). 3-7 (Cycloalkyl). In some embodiments, the cycloalkyl group has 3-6 cyclic carbon atoms (C66-C66). 3-6 (Cycloalkyl). In some embodiments, the cycloalkyl group has 4-6 cyclic carbon atoms (C66-C66). 4-6 (Cycloalkyl). In some embodiments, the cycloalkyl group has 5-6 cyclic carbon atoms (C66-C66). 5-6 (Cycloalkyl). In some embodiments, the cycloalkyl group has 5-10 cyclic carbon atoms (C10-C20). 5-10 Cycloalkyl groups. A partially unsaturated cycloalkyl group may be referred to as a "cycloalkenyl" if the carbide ring contains at least one double bond, or as a "cycloynyl" if the carbide ring contains at least one triple bond. Cycloalkyl groups may include monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) groups and spirocyclic groups. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is bicyclic. In some embodiments, the cycloalkyl group is either monocyclic or bicyclic. In some embodiments, the cycloalkyl group is tricyclic. The cycloforming carbon atom of the cycloalkyl group may optionally be oxidized to form an oxo or thio group. Cycloalkyl groups also include cycloalkylene groups. In some embodiments, the cycloalkyl group contains 0, 1, or 2 double bonds. In some embodiments, the cycloalkyl group contains 1 or 2 double bonds (partially unsaturated cycloalkyl). In some embodiments, the cycloalkyl group may be fused with aryl, heteroaryl, cycloalkyl, and heterocyclic alkyl groups. In some embodiments, the cycloalkyl group may be fused with aryl, cycloalkyl, and heterocyclic alkyl groups. In some embodiments, the cycloalkyl group may be fused with aryl and heterocyclic alkyl groups. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl, cyclohepttrienyl, norcamphenyl (bicyclo[2.2.1]heptyl), norpineyl (bicyclo[3.1.1]heptyl), norcareyl (bicyclo[3.1.0]hexyl), bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[4.1.0]heptyl, and so on.

[0075] Unless otherwise specified, “cycloalkylene” means a divalent cycloalkyl group as defined above.

[0076] Unless otherwise specified, "alkoxy" refers to an alkyl group bonded to the remainder of the molecule via an ether oxygen atom. Representative alkoxy groups are those having 1-6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy. As used herein, "alkoxy" includes unsubstituted and substituted alkoxy groups, particularly those substituted by one or more halogens, hydroxyl groups, or methoxy groups. Preferred alkoxy groups are selected from OCH3, OCF3, CHF2O, CF3CH2O, etc. i- PrO, n- PrO, i- BuO、 n- BuO、 t- BuO, HOCH2CH2O or CH3OCH2CH2O.

[0077] Unless otherwise specified, "aryl" refers to a hydrocarbon aromatic group, which can be monocyclic or polycyclic, such as a monocyclic aryl ring fused with one or more carbocyclic aromatic groups. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and phenanthrene.

[0078] Unless otherwise specified, "aryloxy group" refers to an aryl group bonded to the rest of the molecule via an ether oxygen atom. Examples of aryloxy groups include, but are not limited to, phenoxy and naphthoxy groups.

[0079] Unless otherwise specified, "arylene" refers to a divalent aryl group as defined above. Examples of arylene groups include, but are not limited to, 1,4-phenylene, 1,3-phenylene, 1,2-phenylene, naphthylene, and phenanthrene.

[0080] Unless otherwise specified, "heteroaryl" refers to a substituted or unsubstituted aromatic group containing one or more heteroatoms, the heteroatoms being independently selected from O, N, or S. The number of heteroatoms is preferably 1, 2, 3, or 4, preferably a 5-14-membered aromatic group containing 1-4 heteroatoms selected from oxygen, sulfur, and nitrogen; more preferably a 5-9-membered aromatic group containing 1-2 heteroatoms optionally selected from oxygen, sulfur, or nitrogen; and even more preferably a 5-6-membered aromatic group containing 1-3 heteroatoms optionally selected from oxygen, sulfur, or nitrogen. The heteroaryl group can be monocyclic or polycyclic. A monocyclic heteroaryl group is preferably a 5-6-membered aromatic group containing 1-3 heteroatoms optionally selected from oxygen, nitrogen, or sulfur. More preferably a 5-6-membered aromatic group containing 1-2 heteroatoms optionally selected from oxygen, nitrogen, or sulfur. Even more preferably a 5-6-membered aromatic group containing 1 heteroatom optionally selected from oxygen, nitrogen, or sulfur. In some embodiments, the monocyclic heteroaryl ring is fused with one or more carbocyclic aromatic groups or other monocyclic heterocyclic alkyl groups. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, pyrazinyl, quinolinyl, isoquinolinyl, quinazolinyl, furanyl, thiopheneyl, isoxazolyl, thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, isothiazolyl, pyrroloyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothiaphenyl, benzooxazolyl, benzopyridyl, pyrrolopyrimidinyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-c]pyridyl, 1H-pyrrolo[3,2-c]pyridyl, 1H-pyrrolo[2,3-b]pyridyl.

[0081] Unless otherwise specified, “hybrid aryl” refers to a divalent heteroaryl group as defined above.

[0082] Unless otherwise specified, "heterocyclic alkyl" refers to a non-aromatic ring or ring system that may optionally contain one or more alkenyl groups as part of a ring structure, having at least one heteroatom ring member independently selected from boron, phosphorus, nitrogen, sulfur, oxygen, and selenium, preferably containing 1-4 heteroatoms selected from oxygen, sulfur, or nitrogen, and more preferably containing 1-2 heteroatoms selected from oxygen, sulfur, or nitrogen. In some embodiments, the heterocyclic alkyl is a 5-14 membered non-aromatic ring containing a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-14 membered heterocyclic alkyl). In some embodiments, the heterocyclic alkyl is a 3-9 membered non-aromatic ring containing a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (3-9 membered heterocyclic alkyl). In some embodiments, the heterocyclic alkyl group is a 5-8 membered non-aromatic ring containing a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-8 membered heterocyclic alkyl group). In some embodiments, the heterocyclic alkyl group is a 5-6 membered non-aromatic ring containing a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-6 membered heterocyclic alkyl group). In some embodiments, the 5-6 membered heterocyclic alkyl group contains 1-3 cyclic heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclic alkyl group contains 1-2 cyclic heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclic alkyl group contains 1 cyclic heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl group is a 10-13 membered non-aromatic ring containing a cyclic carbon atom and 1-4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (10-13 membered heterocyclic alkyl group). In some embodiments, the 10-13 membered heterocyclic alkyl group contains 1-3 cyclic heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the 10-13 membered heterocyclic alkyl group contains 1-2 cyclic heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the 10-13 membered heterocyclic alkyl group contains 1 cyclic heteroatom independently selected from nitrogen, oxygen, and sulfur. If the heterocyclic alkyl group contains at least one double bond, then the partially unsaturated heterocyclic alkyl group may be referred to as a "heterocyclic alkenyl group," or if the heterocyclic alkyl group contains at least one triple bond, then the partially unsaturated heterocyclic alkyl group may be referred to as a "heterocyclic ynyl group." Heterocyclic alkyl groups may include monocyclic, bicyclic, spirocyclic, or polycyclic (e.g., having two fused or bridging rings) ring systems. In some embodiments, the heterocyclic alkyl group is a monocyclic group having 1, 2, or 3 heteroatoms independently selected from nitrogen, sulfur, and oxygen. The cyclic carbon atoms and heteroatoms of the heterocyclic alkyl group may optionally be oxidized to form oxo or thio groups or other oxidized bonds (e.g., C(O), S(O), C(S) or S(O)2, N-oxides, etc.), or the nitrogen atom may be quaternized. The heterocyclic alkyl group may be linked via cyclic carbon atoms or cyclic heteroatoms. In some embodiments, the heterocyclic alkyl group contains 0 to 3 double bonds.In some embodiments, the heterocyclic alkyl group contains 0 to 2 double bonds. The definition of heterocyclic alkyl also includes portions of an aromatic ring (also called partially unsaturated heterocycles) having one or more aromatic rings fused to (i.e., sharing bonds with) the heterocyclic alkyl ring, such as benzo[a] derivatives of piperidine, morpholine, aziridine, or tetrahydrothiophene, and pyrido[a] derivatives of piperidine, morpholine, aziridine, or tetrahydrothiophene. Heterocyclic alkyl groups containing fused aromatic rings can be linked via any cyclizing atom, including the cyclizing atom of the fused aromatic ring. Examples of heterocyclic alkyl groups include, but are not limited to, azirrobutyl, azirroheptyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, N-morpholinyl, 3-oxabicyclo[3.1.0]hexyl, 3-oxa-9-azaspiro[5.5]undecyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, oxoperazinyl, pyranyl, pyrrolidinyl, quininyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, scopolamine, 4,5,6,7-tetrahydrothiazo[5,4-c]pyridinyl, 4,5,6,7 -Tetrahydro-1H-imidazo[4,5-c]pyridine, N-methylpiperidinyl, tetrahydroimidazolyl, pyrazolyl, butyrolactam, valproic acid, imidazolinone, hydantoin, dioxolane, phthalimide, pyrimidin-2,4(1H,3H)-diketoyl, 1,4-dioxane, morpholinyl, thiomorpholinyl, thiomorpholin-S-oxide, thiomorpholin-S,S-oxide, piperazine, pyranyl, pyridinone, 3-pyrrololinyl, thiaranyl, pyranone, tetrahydrothiophene, 2-azaspiro[3,3]heptyl, indololinyl. Unless otherwise specified, “heterocyclic alkylene” means a divalent heterocyclic alkylene as defined above.

[0083] Unless otherwise specified, "heterocyclic spirocyclic alkyl" refers to a polycyclic cyclic hydrocarbon group formed by two or more saturated or partially unsaturated monocyclic rings sharing a single carbon atom (called a spiro atom), wherein one or more (e.g., 1, 2, or 3) ring atoms are selected from nitrogen, oxygen, or S(O). p(Where p is an integer from 0 to 2) heteroatoms, with the remaining ring atoms being carbon. When the heteroatom is a nitrogen atom, the nitrogen atom can be substituted or unsubstituted (i.e., N or NR, where R is hydrogen or other substituents already defined herein). Each monocycle may contain one or more double bonds, but no ring has a fully conjugated π-electron system. Spirocycloheterocyclic groups are classified as monospirocycloheterocyclic, bispirocycloheterocyclic, or polyspirocycloheterocyclic groups based on the number of shared spiro atoms between rings. The term "(5-15-membered) heterocyclic spirocycloalkyl" refers to a heterocyclic spirocycloalkyl having 5 to 15 ring atoms, wherein the monocycles sharing the spiro atom are 3 to 8-membered monocycles, and at least one monocycle is a heterocyclic alkyl ring. Preferably, it is a (6-18-membered) heterocyclic spirocycloalkyl having 6 to 18 ring atoms, wherein 1 to 3 ring atoms are heteroatoms; more preferably, it is a (7-15-membered) heterocyclic spirocycloalkyl having 7 to 15 ring atoms, wherein 1 to 3 ring atoms are heteroatoms. The most preferred are 9-membered (4-membered monocyclic (heterocyclic) alkyl groups / 6-membered monocyclic (heterocyclic) alkyl groups, 5-membered monocyclic (heterocyclic) alkyl groups / 5-membered monocyclic (heterocyclic) alkyl groups, 10-membered (5-membered monocyclic (heterocyclic) alkyl groups / 6-membered monocyclic (heterocyclic) alkyl groups, or 11-membered (6-membered monocyclic (heterocyclic) alkyl groups / 6-membered monocyclic (heterocyclic) alkyl groups. Specific examples of heterocyclic spirocyclic alkyl groups include, but are not limited to, those listed below.

[0084] Unless otherwise specified, "oxo" refers to =O; for example, a group formed by substituting carbon with one oxo group is a "carbonyl". The group formed by the substitution of sulfur with one oxo group is "thionyl". The group formed by the substitution of sulfur with two oxo groups is a "sulfonyl group".

[0085] Unless otherwise specified, "halogen" (or halogenated group) means fluorine, chlorine, bromine or iodine. The term "halogenated" (or "halogen substituted") appearing before the group name indicates that the group is partially or completely halogenated, that is, substituted by F, Cl, Br or I in any combination, preferably substituted by F or Cl.

[0086] Unless otherwise specified, the term "substituted" means that one or more hydrogen atoms on a specified atom or group are substituted by one or more substituents other than hydrogen atoms, without exceeding the normal valence of the specified atom. For example, one or more hydrogen atoms of alkyl, alkylene, alkenyl, alkynyl, hydroxyl, or amino groups may be substituted by one or more substituents. The substituents mentioned include, but are not limited to, alkyl, alkenyl, alkynyl, acyl, amino, amide, amidyl, aryl, azide, carbamoyl, carboxyl, carboxylic acid ester, cyano, guanidinyl, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclic, hydroxyl, hydrazyl, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thion, or combinations thereof. The definition of "substituted" does not include similar indeterminate structures obtained by defining substituents having further substituents attached to infinity (e.g., a substituted aryl group having a substituted alkyl group itself substituted by a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.). Unless otherwise specified, the maximum number of successive substitutions in the compounds described herein is three. For example, the successive substitution of a substituted aryl group by two other substituted aryl groups is limited to ((substituted aryl) substituted aryl) substituted aryl. Similarly, the above definition does not include disallowed substitution patterns (e.g., a methyl group substituted with five fluorine atoms or a heteroaryl group having two adjacent oxygen ring atoms). Such disallowed substitution patterns are well known to those skilled in the art. Whenever used to modify a chemical group, “substituted” may describe other chemical groups as defined herein. For example, the term “substituted aryl” includes, but is not limited to, “alkylaryl.” Unless otherwise specified, if a group is described as optionally substituted, any substituted elements of that group are themselves unsubstituted.

[0087] "Optional" or "optionally" means that the event or condition described below may, but is not required, occur, and the description includes both the scenario in which the event or condition occurs and the scenario in which the event or condition does not occur.

[0088] Unless otherwise specified, "acyl" means -C(=O)-R, where R is selected from optionally substituted alkyl, alkenyl, ynyl, cycloalkyl, cycloalkenyl, cycloynyl, aryl, heteroaryl or heterocycloalkyl.

[0089] Unless otherwise specified, the word “comprising”, or variations thereof such as “including” or “containing”, may be understood to mean including the stated element or integer, or a group of elements or integers, but does not exclude any other element or integer, or a group of elements or integers.

[0090] The substituent "-O-CH2-O-" indicates that the two oxygen atoms in the substituent are connected to two adjacent carbon atoms of a heterocyclic alkyl, aryl, or heteroaryl group. For example:

[0091] When the number of a linking group is 0, such as -(CH2)0-, it indicates that the linking group is a single bond.

[0092] When one of the variables is selected as a chemical bond, it means that the two groups connected are directly linked. For example, when L in XLY represents a chemical bond, it means that the structure is actually XY.

[0093] The term "membered ring" includes any ring structure. The term "membered" refers to the number of skeleton atoms that make up the ring. For example, cyclohexyl, pyridyl, pyranyl, and thioranyl are six-membered rings, while cyclopentyl, pyrroleyl, furanyl, and thiophenyl are five-membered rings.

[0094] The term "fragment" refers to a specific part or functional group of a molecule. Chemical fragments are generally considered to be chemical entities contained in or attached to a molecule.

[0095] The term "isomer" refers to any tautomer, stereoisomer, transisomer, isotopic isomer, enantiomer, or diastereomer of any compound of the present invention. The compounds of the present invention may have one or more chiral centers or double bonds, and thus exist in stereoisomeric form, such as double-bonded isomers (i.e., E / Z geometric isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis / trans isomers). Therefore, the compounds of the present invention encompass all corresponding stereoisomers, i.e., stereoisomerically pure (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) forms, as well as mixtures of enantiomers and stereoisomers, such as racemates. The enantiomers and stereoisomers of the compounds of this invention can be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral gas chromatography, chiral high-performance liquid chromatography, and by crystallizing the compounds as chiral salt complexes or by crystallizing the compounds in chiral solvents. The enantiomers and stereoisomers can also be obtained by well-known asymmetric synthetic methods using stereoisomerically pure or enantiomerically pure intermediates, reagents, and catalysts.

[0096] The term "isotope isomers" refers to different molecules that are identical in structure except for their isotopes.

[0097] The term "restricted transisomer" refers to a conformational stereoisomer that arises when rotation around a single bond within a molecule is prevented or significantly slowed by spatial interactions with other parts of the molecule, and when the substituents at the ends of the single bond are asymmetrical; that is, a restricted transisomer does not require a stereocenter. When the rotational barrier around the single bond is sufficiently high and the interconversion between conformations is sufficiently slow, the separation of individual isomers is permissible (LaPlante et al., J.Med.Chem. 2011, 54, 20, 7005), preferably by chiral resolution.

[0098] Unless otherwise specified, when a group has one or more connectable sites, any one or more sites of that group can be linked to other groups by chemical bonds. When the chemical bond connection is non-directional and the connectable site contains H atoms, the number of H atoms at that site will decrease accordingly with the number of chemical bonds being connected, resulting in a group with a corresponding valence. For example, "pyridyl" indicates... "Oxazolyl" indicates "Bicyclo[4.1.0]heptyl" indicates

[0099] Unless otherwise specified, use wedge-shaped solid line keys. and wedge-shaped dashed key The absolute configuration of the center of a solid is represented by a straight solid line key. and straight dashed key The relative configuration of the center of a solid is indicated by a wavy line. Indicates wedge-shaped solid line key or wedge-shaped dashed key Or use wavy lines Indicates a straight solid line key Or straight dashed key

[0100] Unless otherwise stated, use Indicates a single bond or a double bond.

[0101] Specific pharmaceutical and medical terminology

[0102] The term “acceptable,” as used herein, means that a prescription component or active ingredient does not have an excessively harmful effect on health for general therapeutic purposes.

[0103] The terms “treatment,” “treatment process,” or “therapy” as used herein include alleviating, suppressing, or improving symptoms or conditions of a disease; suppressing the development of complications; improving or preventing underlying metabolic syndrome; suppressing the development of a disease or symptom, such as controlling the progression of a disease or condition; reducing a disease or symptom; reducing a disease or symptom; reducing complications arising from a disease or symptom, or preventing or treating signs arising from a disease or symptom.

[0104] As used herein, a compound or pharmaceutical composition, when administered, can improve a disease, symptom, or condition, particularly by improving its severity, delaying its onset, slowing its progression, or reducing its duration. This may be attributable to or related to the administration, whether administered regularly or intermittently.

[0105] "Active ingredient" refers to the compounds of this invention, as well as pharmaceutically acceptable inorganic or organic salts of the compounds of this invention. The compounds of this invention may contain one or more asymmetric centers and thus appear as racemates, racemic mixtures, single enantiomers, diastereomers, and single diastereomers. The asymmetric centers that may exist depend on the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible optical isomers and diastereomer mixtures, as well as pure or partially pure compounds, are included within the scope of this invention. This invention means including all such isomeric forms of these compounds.

[0106] The terms “compound,” “composition,” “agent,” or “medicine or medicament” may be used interchangeably here, and all refer to a compound or composition that, when applied to an individual (human or animal), can induce a desired pharmaceutical and / or physiological response through local and / or systemic action.

[0107] The term “administered, administering, or administration” here refers to the direct application of the compound or composition described herein, or the application of a prodrug, derivative, or analog of the active compound.

[0108] While the numerical ranges and parameters used to define the broader scope of this invention are approximate values, the relevant values ​​in the specific embodiments have been presented as precisely as possible. However, any value inevitably contains standard deviations due to individual test methods. Here, "approximately" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "approximately" may mean that the actual value falls within the acceptable standard error of the mean, as determined by those skilled in the art. Except for experimental examples, or unless explicitly stated otherwise, it is understood that all ranges, quantities, values, and percentages used herein (e.g., to describe material usage, duration, temperature, operating conditions, quantity ratios, and others similar) are modified with "approximately". Therefore, unless otherwise stated, the numerical parameters disclosed in this specification and the accompanying claims are approximate values ​​and are subject to change as needed. At a minimum, these numerical parameters should be understood as the indicated significant digits and values ​​obtained using general rounding.

[0109] Unless otherwise defined in this specification, scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art. Furthermore, unless conflicting with the context, singular nouns used herein include their plural forms, and vice versa.

[0110] Therapeutic uses

[0111] This invention provides methods for treating diseases using compounds or pharmaceutical compositions of the general formula of this invention, including but not limited to conditions involving RAS (e.g., cancer).

[0112] In some embodiments, a method for treating cancer is provided, the method comprising administering to an individual in need an effective amount of any of the aforementioned pharmaceutical compositions comprising a compound of the general structural formula. In some embodiments, the cancer is mediated by the renal arterial system (RAS). In other embodiments, the cancer is a hematologic malignancy and a solid tumor, including but not limited to leukemia, breast cancer, lung cancer, pancreatic cancer, colon cancer, bladder cancer, brain cancer, urothelial carcinoma, prostate cancer, liver cancer, ovarian cancer, head and neck cancer, gastric cancer, mesothelioma, or all metastatic cancers.

[0113] route of administration

[0114] The compounds of this invention and their pharmaceutically acceptable salts can be formulated into various preparations, comprising, within a safe and effective range, the compounds of this invention or their pharmaceutically acceptable salts and pharmacologically acceptable excipients or carriers. "Safe and effective range" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. The safe and effective range of the compound is determined based on the age, condition, and duration of treatment of the patient.

[0115] "Pharmaceutically acceptable excipients or carriers" refers to one or more compatible solid or liquid fillers or gelling substances that are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with and with the compounds of the present invention without significantly reducing the efficacy of the compounds. Examples of pharmacologically acceptable excipients or carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), and polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.). Wetting agents (such as sodium dodecyl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0116] When applying the compounds of this invention, they can be administered orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), or topically.

[0117] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following components: (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silica; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or cassava starch, alginate, certain complex silicates, and sodium carbonate; (e) slowing agents, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. Buffers may also be included in capsules, tablets, and pills.

[0118] Solid dosage forms such as tablets, sugar pills, capsules, pellets, and granules can be prepared using coatings and shells, such as casings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compound from such compositions can be delayed in a portion of the digestive tract. Examples of encapsulating components that can be used are polymeric substances and waxes. If necessary, the active compound may also be formed into microcapsules with one or more of the excipients described above.

[0119] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, e.g., ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.

[0120] In addition to these inert diluents, the composition may also contain auxiliaries such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and fragrances.

[0121] In addition to the active compound, the suspension may contain suspending agents such as ethoxylated isooctadecyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitol esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0122] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.

[0123] Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays, and inhalers. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be necessary.

[0124] The compounds of this invention can be administered alone or in combination with other pharmaceutically acceptable compounds. When using the pharmaceutical composition, a safe and effective amount of the compound of this invention is applied to the mammal (such as a human) requiring treatment, wherein the dose administered is a pharmaceutically considered effective dose. For a person weighing 60 kg, the daily dose is typically 1–2000 mg, preferably 50–100 mg. Of course, the specific dosage should also consider factors such as the route of administration and the patient's health condition, which are within the scope of a skilled physician's expertise.

[0125] The features mentioned above in this invention, or the features mentioned in the embodiments, can be combined arbitrarily. All features disclosed in this specification can be used in any compositional form, and each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equivalent, or similar purpose. Therefore, unless otherwise specified, the disclosed features are merely general examples of equivalent or similar features. Detailed Implementation

[0126] The following description will elaborate on the specific aspects, characteristics, and advantages of the aforementioned compounds, methods, and pharmaceutical compositions, making the content of this invention readily apparent. It should be understood that the detailed descriptions and examples described below are specific embodiments and are for reference only. After reading this description, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by this application.

[0127] In all embodiments, 1 H-NMR was recorded using a Vian Mercury 400 NMR spectrometer, and chemical shifts are expressed as δ (ppm). Unless otherwise specified, the silica gel used for separation was 200-300 mesh, and all eluent ratios were by volume.

[0128] The following abbreviations are used in this invention: ACN represents acetonitrile; (Boc)₂O represents ditert-butyl dicarbonate; B₂(OH)₄ represents tetrahydroxydiboron; B₂pin₂ represents dipinanolyldiboron; CDCl₃ represents deuterated chloroform; Cs₂CO₃ represents cesium carbonate; CuI represents cuprous iodide; DCM represents dichloromethane; DIPEA represents diisopropylethylamine; Diox represents 1,4-dioxane; DMF represents N,N-dimethylformamide; DMAP represents 4-(dimethylamino)pyridine; DMSO represents dimethyl sulfoxide; EA represents ethyl acetate; EtOH represents anhydrous ethanol; EDCI represents 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; Et₃SiH represents... Table 1: Triethylsilane; Flash represents rapid medium-pressure preparative chromatography; Hexane represents n-hexane; Heptane represents n-heptane; HBpin represents pinacol borane; HCl represents hydrochloric acid; HATU represents 2-(7-azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate; HPLC represents high-performance liquid chromatography; hr represents hours; HOBt represents 1-hydroxybenzotriazole; [Ir(COD)(OMe)]2 represents (1,5-cyclooctadiene)methoxyiridium(I) dimer; K2CO3 represents potassium carbonate; K3PO4 represents potassium phosphate; KOAc represents potassium acetate; KOH represents potassium hydroxide; KOPiv represents potassium tert-pentanol; LC-MS represents... Mass spectrometry; LiOH represents lithium hydroxide; LDA represents lithium diisopropylamino; LiBH4 represents lithium borohydride; MeOH represents methanol; mL represents milliliters; min represents minutes; NaH represents sodium hydride; NaHCO3 represents sodium bicarbonate; NBS represents N-bromosuccinimide; NIS represents N-iodosuccinimide; NMR represents nuclear magnetic resonance; NMM represents N-methylmorpholine; NMI represents N-methylimidazolium; PE represents petroleum ether; Pre-TLC indicates thin-layer chromatography; Pd / C represents palladium on carbon; Pd(OH)2 represents palladium hydroxide; Pd(PPh3)4 represents tetrakis(triphenylphosphine)palladium; Pd2(dba)3 represents tris(dibenzylideneacetone)dipalladium(0); Pd(dp pf)Cl2 represents 1,1'-bis(diphenylphosphino)ferrocene palladium(II) dichloride; Pd(dtbpf)Cl2 represents 1,1'-bis(di-tert-butylphosphino)ferrocene palladium dichloride; PdCl2 represents palladium dichloride; Pd(PPh3)2Cl2 represents bis(triphenylphosphino) palladium dichloride; POCl3 represents phosphorus oxychloride; PPh3 represents triphenylphosphine; Py represents pyridine; SOCl2 represents thionyl chloride; TBAF represents tetrabutylammonium fluoride; TBDPSCl represents tert-butyldiphenylchlorosilane; TBSCl represents tert-butyldimethylchlorosilane; TFA represents trifluoroacetic acid; TLC represents thin-layer chromatography; TEA represents triethylamine; THF represents tetrahydrofuran; Tol represents toluene;XantPhos represents 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthracene; XPhos represents 2-dicyclohexylphosphine-2′,4′,6′-triisopropylbiphenyl; XPhos-Pd-G3 represents methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II); 2-MeTHF represents dimethyltetrahydrofuran.

[0129] Preparation Example 1: Synthesis of IntA1:

[0130] Synthesize IntA1-1:

[0131] Trimethyl phosphonoacetate (124 g, 0.681 mol) and THF (2 L, ultra-dry) were added to a 3 L three-necked flask. After purging with argon, the mixture was cooled to -10 °C in an ice-salt bath. Then, NaH (34 g, 60%, 0.851 mol) was added slowly in portions. After the addition was complete, the mixture was stirred at 0–5 °C for 1 h. Then, a THF (200 mL) solution of 100 g, 0.567 mol of 3-(benzyloxy)-1-cyclobutanone was slowly added dropwise under ice bath. After the addition was complete, the system was allowed to rise naturally to room temperature, and the reaction was stirred under argon protection for 2 h. After the reaction was completed, the mixture was cooled again in an ice bath and then quenched dropwise with saturated ammonium chloride solution (500 mL). Add EA (1L) and water (2L), stir, separate the layers, extract the aqueous phase with EA (500mL), combine the organic phases, wash twice with saturated sodium chloride solution (1L*2), concentrate, and purify the residue by column chromatography (PE:EA = 40:0 to 40:1 to 30:1). Obtain a colorless oily product (88.3g, yield: 67.1%).

[0132] LC-MS: m / z = 233[M+1] + .

[0133] Synthesize IntA1-2:

[0134] Add the above compound IntA1-1 (88.3 g, 0.381 mol), MeOH (1.5 L), and... to a 3 L single-necked flask.

[0135] 10% Pd / C (8.8 g, wet: 55%) was purged with hydrogen three times, and then reacted vigorously with a hydrogen bag at room temperature for 20 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filter cake was washed with anhydrous methanol. The filtrate was concentrated to dryness to give a colorless oily product (52.5 g, yield: 95.9%).

[0136] LC-MS: m / z = 145 [M+1] + .

[0137] Synthesize IntA1-3:

[0138] Add the above-mentioned compound IntA1-2 (52.5 g, 0.364 mol), DCM (600 mL), imidazole (37.1 g, 0.547 mol), and DMAP (8.9 g, 0.072 mol) to a 3 L three-necked flask. Cool the mixture to 0–5 °C in an ice bath under argon protection, and then slowly add a DCM solution of TBSCl (82.4 g, 0.547 mol) in 200 mL. After the addition is complete, stir the mixture at room temperature for 20 h. After the reaction is complete as detected by LC-MS, add water (1 L), stir, separate the liquids, and wash the organic phase successively with 10% citric acid solution (500 mL) and saturated sodium chloride solution (500 mL). Dry the mixture with anhydrous sodium sulfate, filter, and concentrate to dryness to obtain the crude product.

[0139] Synthesis of IntA1-4:

[0140] The above-mentioned compound IntA1-3 (crude product, 0.364 mol), THF (300 mL), MeOH (300 mL), water (100 mL), and lithium hydroxide monohydrate (30.6 g, 0.728 mol) were added to a 3 L three-necked flask. The mixture was stirred at room temperature for 4 h under argon protection. After the reaction was completed as detected by LC-MS, the mixture was concentrated to about 1 / 3 of its original volume, diluted with water (500 mL), and washed twice with EA (200 mL * 2). The aqueous phase was then adjusted to pH 4-5 with 2N HCl in an ice bath, extracted twice with EA (300 mL * 2), and the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give a pale yellow oily product (86.4 g, yield: 97.1%).

[0141] LC-MS: m / z = 243 [M-1] - .

[0142] Synthesize IntA1-5:

[0143] The above-mentioned compounds IntA1-4 (86.4 g, 0.354 mol), DCM (1 L), (S)-4-benzyl-2-azolidinone (69.0 g, 0.389 mol), TEA (107.3 g, 1.062 mol), and DMAP (4.32 g, 0.035 mol) were added to a 2 L single-necked flask. After argon purging protection, the mixture was cooled to 0–5 °C in an ice bath. Then, 2-chloro-1-methylpyridine iodide (135.7 g, 0.531 mol) was slowly added in portions. After the addition was complete, the mixture was stirred at room temperature for 20 h. After the reaction was detected by LC-MS, water (500 mL) was added to the mixture, stirred, and separated. The aqueous phase was extracted with DCM (200 mL), and the combined organic phases were washed with saturated sodium chloride solution (500 mL), concentrated, and the residue was purified by column chromatography (PE:EA = 20:0 to 20:1 to 10:1) to give a white solid product (143 g, yield: 100%).

[0144] LC-MS: m / z = 404.3 [M+1] + .

[0145] Synthesizing IntA1-6:

[0146] Add the above compound IntA1-5 (143 g, 0.354 mol) and THF (700 mL) to a 2 L single-necked flask. After dissolving by stirring at room temperature, add 2N HCl (531 mL, 1.062 mol). Stir the mixture at room temperature for 2 h. After the reaction is complete as detected by LC-MS, add EA (300 mL), stir, separate the phases, and extract the aqueous phase with EA (200 mL * 2). Combine the organic phases and wash successively with saturated sodium chloride solution (500 mL), saturated sodium bicarbonate solution (500 mL), and saturated sodium chloride solution (500 mL). Dry with anhydrous sodium sulfate, filter, and concentrate to dryness to give a brown oily product (100 g, yield: 97.7%).

[0147] LC-MS: m / z = 290.3 [M+1] + .

[0148] Synthesize IntA1-7:

[0149] The above-mentioned compounds IntA1-6 (85.3 g, 0.295 mol), DCM (1.28 L), imidazole (30.1 g, 0.443 mol), and PPh3 (116 g, 0.443 mol) were added to a 2 L single-necked flask. The mixture was cooled to 0–5 °C in an ice bath, and then iodine (112.5 g, 0.443 mol) was added in portions at room temperature. After the addition was complete, the mixture was heated to 30–40 °C and stirred for 20 h. After the reaction was completed by LC-MS stirring, the mixture was cooled, filtered, and the filter cake was washed with a small amount of PE. The filtrate was concentrated, and the residue was purified by column chromatography (PE:EA = 4:0 to 4:1) to give an off-white solid product (108 g, yield: 91.7%).

[0150] LC-MS: m / z = 400.2 [M+1] + .

[0151] Synthesizing IntA1-8:

[0152] The above-mentioned compound IntA1-7 (66.5 g, 0.167 mol) and THF (800 mL, ultra-dry) were added to a 1 L three-necked flask. Under argon protection, the mixture was cooled to -70–-80 °C, and then kept at -65 °C with dropwise addition of LDA (208 mL, 2 M in THF, 0.416 mol). After the addition was complete, the mixture was kept at -65–-70 °C with stirring for 2 h. The temperature was then lowered again to -70–-80 °C, and di-tert-butyl azodicarbonate (46 g, 0.20 mol) was added dropwise, controlled below -65 °C. After the addition was complete, the mixture was kept at this temperature for 2 h. Then, N,N-dimethylpropenylurea (124 g, 0.97 mol) was added dropwise at -65–-70 °C. After the addition was complete, the mixture was allowed to rise naturally to room temperature with stirring for 4 h. LC-MS analysis showed that most of the intermediates were unclosed ring-closed. The mixture was then further heated to 60 °C with stirring for 8 h. After the intermediate disappeared as detected by LC-MS, the system was cooled to room temperature, and then water (400 mL) and lithium hydroxide monohydrate (14.4 g, 0.343 mol) were added. The mixture was stirred at room temperature for 2 h. After the reaction was completed as detected by LC-MS, EA (400 mL) was added, the mixture was stirred, and the liquid was separated. The organic phase was extracted with water (400 mL), and the combined aqueous phases were washed with EA (300 mL * 3). The combined aqueous phases were adjusted to pH 4-5 with 2N HCl, and then extracted with EA (200 mL * 3). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to give a brown oily impurity product (44 g, yield: 77.0%, Chiral HPLC: 80.5% vs. 19.5%).

[0153] LC-MS: m / z = 341.2 [M-1] - .

[0154] Synthesize IntA1-9:

[0155] The above-mentioned compound IntA1-8 (44 g, impurity, 0.129 mol), DMF (400 mL), K2CO3 (53.3 g, 0.386 mol), and benzyl bromide (22 g, 0.129 mol) were added to a 1 L single-necked flask. The mixture was stirred at room temperature for 20 h. After the reaction was completed as detected by LC-MS, water (400 mL) and EA (200 mL) were added to the mixture, stirred, and separated. The aqueous phase was extracted again with EA (200 mL). The combined organic phases were washed with saturated sodium chloride solution, concentrated, and the residue was purified by column chromatography (PE:EA = 20:0 to 20:1 to 10:1) to give a brown oily product (19.5 g, yield: 34.9%, chiral HPLC analysis showed that the isomer ratio was 81%:19%).

[0156] LC-MS: m / z = 433.3 [M+1] + .

[0157] Synthesize IntA1:

[0158] The above-mentioned compound IntA1-9 (19.07 g, 44.1 mmol), DCM (100 mL), and TFA (57 mL) were added to a 250 mL single-necked flask, and the mixture was stirred at room temperature for 4 h. After the reaction was completed as detected by LC-MS, the mixture was concentrated, and the residue was flash purified (0.1% TFA / ACN system), lyophilized, and a pale yellow gelatinous product (15.6 g, TFA salt, yield: 100%) was obtained.

[0159] LC-MS: m / z = 233.2 [M+1] + .

[0160] Preparation Example 2: Synthesis of IntB1:

[0161] Synthesize IntB1-1:

[0162] 5-Fluoro-3-bromo-2-cyanopyridine (25 g, 124.38 mmol), THF (275 mL), TEA (12.59 g, 124.38 mmol), and 1-methylpiperazine (18.69 g, 186.57 mmol) were added to a 500 mL single-necked flask, and the mixture was heated to 60 °C and stirred for 8 h. After the reaction was confirmed to be complete by LC-MS, the mixture was concentrated and extracted three times with water (150 mL), saturated sodium bicarbonate solution (50 mL), and EA (100 mL * 3). The organic phases were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was then slurried with PE (100 mL) and filtered to obtain a solid compound IntB1-1 (34.9 g, Y: 99%).

[0163] LC-MS: m / z = 281[M+1] + .

[0164] Synthesize IntB1-2:

[0165] IntB1-1 (20.7 g, 73.62 mmol) and anhydrous THF (350 mL) were added to a 1 L three-necked flask. After argon protection, the mixture was cooled to -5 to 0 °C, and methyl magnesium bromide (3 M, 98 mL) was added dropwise. After the addition was complete, the mixture was reacted at 0 °C for 0.5 h, and then at room temperature for 2 h. After the reaction was confirmed to be complete by LC-MS, saturated ammonium chloride (200 mL) was added to quench the reaction, followed by the addition of saturated sodium chloride (100 mL). The mixture was extracted three times with EA (200 mL * 3), the organic phases were combined, washed with saturated sodium chloride, concentrated, and purified by column chromatography to obtain compound IntB1-2 (17.58 g, Y: 80%).

[0166] LC-MS: m / z = 298 [M+1] + .

[0167] Synthesize IntB1-3:

[0168] Formic acid (21.15 g, 459.45 mmol) was added to a 500 mL three-necked flask. After argon protection, the mixture was cooled to 0 °C, and TEA (239 g, 2.362 mol) was added dropwise. Then (S,S)-N-(p-toluenesulfonyl)-1,2-diphenylethanediamine (p-isopropylbenzene)ruthenium chloride (877 mg, 1.378 mmol) was added, and the mixture was heated to 40 °C and stirred for 15 minutes. The mixture was then cooled to room temperature, and IntB1-2 (27.4 g, 91.89 mmol) was added in portions. The mixture was then heated to 50 °C and reacted overnight. After the reaction was confirmed to be complete by LC-MS, the reaction solution was directly concentrated, and the crude product was purified by column chromatography to obtain compound IntB1-3 (27.3 g, Y: 98%, ee%: 93.7%).

[0169] LC-MS: m / z = 300[M+1] + .

[0170] Synthesis of IntB1-4:

[0171] IntB1-3 (20.7 g, 68.95 mmol) and DMF (210 mL) were added to a 500 mL three-necked flask. After argon protection, the mixture was cooled to 0 °C, and NaH (3.31 g, 82.74 mmol, 60%) was added in portions. The reaction was carried out at 0 °C for 1 h. Then, iodomethane (10.77 g, 75.85 mmol) was added dropwise, and the reaction was continued at 0 °C for 2 h. After the reaction was confirmed to be complete by LC-MS, saturated ammonium chloride (100 mL) was added dropwise to quench the reaction mixture, followed by the addition of saturated sodium chloride (200 mL). The mixture was extracted four times with EA (300 mL * 4), the organic phases were combined, concentrated, and the crude product was purified by rapid column chromatography to obtain compound IntB1-4 (15.354 g, Y: 70%).

[0172] LC-MS: m / z = 314.1 [M+1] + .

[0173] Synthesize IntB1-5:

[0174] IntB1-4 (7.264 g, 23.12 mmol) and neopentyl glycol diboronate (13.05 g, 57.79 mmol) were added to a 250 mL single-necked flask and dissolved in Dioxane (150 mL). Then, potassium acetate (5.67 g, 57.79 mmol) and Pd(dppf)Cl2 (1.691 g, 2.31 mmol) were added. After three purgings with argon gas, the mixture was heated to 90 °C and reacted overnight. After LC-MS analysis to confirm the reaction was complete, the reaction solution was filtered, and the filtrate was directly concentrated to obtain the crude compound IntB1-5 (24.95 g).

[0175] LC-MS: m / z = 348.2 [M+1] + .

[0176] Synthesize IntB1-6:

[0177] IntB1-5 (crude product 24.95 g, 23.12 mmol) and IntC3 (18.43 g, 27.74 mmol) were added to a 500 mL single-necked flask and dissolved in Dioxane (200 mL) / H2O (40 mL). Then, potassium carbonate (9.59 g, 69.36 mmol) and Pd(dppf)Cl2 (1.691 g, 2.31 mmol) were added. After three purgings with argon gas, the mixture was heated to 70 °C and reacted overnight. After the reaction was confirmed to be complete by LC-MS, the reaction solution was filtered, the filtrate was concentrated, and the crude product was purified by column chromatography to obtain compound IntB1-6 (20 g, Y: 112%).

[0178] LC-MS: m / z = 771.3 [M+1] + .

[0179] Synthesize IntB1-7:

[0180] IntB1-6 (20 g crude, 23.12 mmol) and THF (400 mL) were added to a 1 L single-necked flask. After argon protection, the mixture was cooled to 0 °C. NaH (4.624 g, 60%, 115.6 mmol) was added in portions, and the mixture was stirred at 0 °C for 0.5 h. Then, iodoethane (5.41 g, 34.68 mmol) was added dropwise, and the reaction was continued at 0 °C for 1 h. Then, iodoethane (4.33 g, 27.74 mmol) was added, and the mixture was allowed to react naturally overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, ice water (50 mL) was added to quench the reaction mixture, followed by the addition of saturated saline (100 mL). The mixture was extracted twice with EA (150 mL * 2), the organic phases were combined, concentrated, and the crude product was purified by column chromatography to obtain compound IntB1-7 (10.6 g, Y: 57.4%).

[0181] LC-MS: m / z = 799.3 [M+1] + .

[0182] Synthesize IntB1-8:

[0183] IntB1-7 (7.99 g, 10 mmol), THF (40 mL), and TBAF (1 M, 40 mL) were added to a 250 mL single-necked flask, and the mixture was reacted overnight at 50 °C. After the reaction was confirmed to be complete by LC-MS, water was added to the reaction solution, and the mixture was extracted three times with DCM. The organic phases were combined, washed with water and saturated sodium chloride, concentrated, and purified by column chromatography to obtain compound IntB1-8 (4.2 g, Y: 74.8%).

[0184] LC-MS: m / z = 561.2 [M+1] + .

[0185] Synthesize IntB1:

[0186] IntB1-8 (1 g, 1.84 mmol) and dibenzoyl borate (701 mg, 2.76 mmol) were added to a 250 mL single-necked flask and dissolved in Tol (10 mL). Then, potassium acetate (361 mg, 3.68 mmol) and Pd(dppf)Cl2 (135 mg, 0.184 mmol) were added. After three purgings with argon gas, the mixture was heated to 90 °C and reacted for 5 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was filtered, the filtrate was concentrated, and purified by column chromatography to obtain compound IntB1 (740 mg, Y: 66%).

[0187] LC-MS: m / z = 609.4 [M+1] + .

[0188] Preparation Example 3: Synthesis of IntB2:

[0189] Synthesize IntB2-1:

[0190] 5-Fluoro-3-bromo-2-cyanopyridine (50 g, 248.8 mmol), THF (500 mL), TEA (25.1 g, 248.8 mmol), and 1-Cbz-piperazine (60.3 g, 273.6 mmol) were added to a 1 L single-necked flask, and the mixture was heated to 60 °C and stirred for 5 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated to approximately 200 mL, and then water (500 mL) was added. Sodium bicarbonate (25 g) was slowly added while stirring at room temperature. After the addition was complete, the mixture was stirred at room temperature for 1 h, filtered, and the filter cake was washed three times with water, dried under vacuum, and then dried to obtain a white solid product (94 g, yield: 94%).

[0191] LC-MS: m / z = 401.1 [M+1] + .

[0192] Synthesize IntB2-2:

[0193] IntB2-1 (72.4 g, 180.5 mmol) and anhydrous THF (1 L) were added to a 2 L three-necked flask. After argon protection, the mixture was cooled to -5 to 0 °C in an ice-salt bath. Methylmagnesium bromide (3 M, 150.5 mL, 451.4 mmol) was added dropwise while maintaining the temperature below 5 °C. After the addition was complete, the mixture was kept at -5 to 5 °C with stirring for 1 h, and then allowed to rise naturally to room temperature for another 20 h with stirring. After the starting material was detected by LC-MS, the mixture was quenched with water (500 mL), and NaOH (10 g) was added. Then Cb2Cl (21.5 g) was added dropwise, and the mixture was stirred at room temperature for another 3 h. After the reaction was detected by LC-MS to be complete, saturated ammonium chloride (500 mL) was added to quench the reaction, and then EA (300 mL * 3) was added to extract three times. The organic phases were combined, washed with saturated sodium chloride, concentrated, and the residue was purified by column chromatography (EA:PE = 4:0 to 4:1 to 2:1 to 1:1) to give the pale yellow compound IntB2-2 (51.4 g, Y: 68%).

[0194] LC-MS: m / z = 418.1 [M+1] + .

[0195] Synthesize IntB2-3:

[0196] Formic acid (28.3 g, 615.0 mmol) was added to a 1 L single-necked flask. After argon protection, the mixture was cooled to 0 °C, and TEA (310.6 g, 3.075 mol) was added dropwise. Then (S,S)-N-(p-toluenesulfonyl)-1,2-diphenylethanediamine (p-isopropylbenzene)ruthenium chloride (1.174 g, 1.845 mmol) was added, and the mixture was heated to 40 °C and stirred for 15 minutes. The mixture was then cooled to room temperature, and IntB2-2 (51.4 g, 123.0 mmol) was added in portions. The mixture was then heated to 50 °C and reacted overnight. After the reaction was confirmed to be complete by LC-MS, the reaction solution was directly concentrated, and the crude product was purified by column chromatography to obtain compound IntB2-3 (49 g, Y: 94.8%, ee%: 95.0%).

[0197] LC-MS: m / z = 420.1 [M+1] + .

[0198] Synthesis of IntB2-4:

[0199] IntB2-3 (24.6 g, 58.53 mmol) and DMF (250 mL) were added to a 500 mL single-necked flask. After argon protection, the mixture was cooled to 0 °C. NaH (2.81 g, 70.23 mmol, 60%) was then added in portions, and the mixture was stirred at 0 °C for 1 h. Then, a DMF (5 mL) solution of iodomethane (9.97 g, 70.23 mmol) was added dropwise. After the addition was complete, the mixture was kept at 0 °C for another 1 h, then allowed to rise naturally to room temperature and stirred for 5 h. After the reaction was confirmed to be complete by LC-MS, saturated ammonium chloride (200 mL) was added dropwise to quench the reaction mixture. Water (300 mL) was then added, and the mixture was stirred at room temperature for 2 h. The mixture was filtered, the filter cake was washed three times with water, and dried under vacuum to obtain a light brown solid product (24 g, Y: 94%).

[0200] LC-MS: m / z = 434.1 [M+1] + .

[0201] Synthesize IntB2-5:

[0202] IntB2-4 (9 g, 20.72 mmol), neopentyl glycol diboronate (7.02 g, 31.08 mmol), Xphos (198 mg, 0.41 mmol), potassium tert-pentoxide (6.1 g, 43.52 mmol), 2-methyltetrahydrofuran (135 mL), and MeOH (45 mL) were added to a 500 mL single-necked flask. After purging the mixture with argon, Xphos-Pd-G3 (175 mg, 0.21 mmol) was added. The mixture was then heated to 70 °C and stirred for 2 h under argon purging protection. After the reaction was completed, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filter cake was washed with Diox. The filtrate was concentrated to dryness, and the crude product was used directly in the next step.

[0203] Synthesizing IntB2-6:

[0204] Add the above-mentioned IntB2-5 (crude, 20.72 mmol), IntC2 (16.1 g, 24.86 mmol), and Dioxane (150 mL) / H2O (30 mL) to a 500 mL single-necked flask, then add potassium carbonate (8.59 g, 62.25 mmol) and Pd(dppf)Cl2 (758 mg, 1.036 mmol). After three argon purging protection cycles, the mixture was heated to 70 °C and reacted overnight. After the reaction was confirmed to be complete by LC-MS, the reaction solution was filtered, the filtrate was concentrated, and the crude product was purified by column chromatography (EA:PE = 3:0 to 3:1 to 2:1 to 1:1) to obtain impurities (12.9 g, Y: 71.3%).

[0205] LC-MS: m / z = 873.3 [M+1] + .

[0206] Synthesize IntB2-7:

[0207] Add IntB2-6 (6.2 g, 7.105 mmol) and DMF (120 mL) to a 250 mL single-necked flask. After argon protection, cool to 0 °C, then add cesium carbonate (6.95 g, 21.315 mmol). Stir the mixture in an ice bath for 0.5 h. Then add iodoethane (2.217 g, 14.21 mmol), and allow the mixture to rise naturally to room temperature while stirring for 20 h. After the reaction is complete as detected by LC-MS, quench the mixture with ice water (200 mL), then add saturated saline (200 mL), and extract twice with EA (150 mL * 2). Combine the organic phases, concentrate, and use the crude product directly for the next step.

[0208] Synthesis of IntB2-8-P1:

[0209] Add the above-mentioned IntB2-7 (crude, 7.105 mmol), THF (80 mL), and TBAF (1 M, 35 mL) to a 250 mL single-necked flask, and react overnight at 50 °C. After the reaction was confirmed to be complete by LC-MS, water was added to the reaction solution, and the mixture was extracted three times with DCM. The organic phases were combined, washed with water and saturated sodium chloride, respectively, concentrated, and the residue was purified by column chromatography (EA:PE = 3:0 to 3:1 to 2:1 to 1:1 to 1:3) to obtain the target axially chiral compound IntB2-8-P1 (2.0 g, Y: 42.5%, the least polar spot) and its isomer IntB2-8-P2 (1.67 g, Y: 35.5%).

[0210] LC-MS: m / z = 663.3 [M+1] + .

[0211] Synthesizing IntB2:

[0212] Add IntB2-8-P1 (2.0 g, 3.018 mmol), boric acid (407 mg, 4.53 mmol), Xphos (30 mg, 0.06 mmol), potassium tert-pentanoxide (889 mg, 6.34 mmol), 2-methyltetrahydrofuran (60 mL), and MeOH (20 mL) to a 50 mL single-necked flask. Then add Xphos-Pd-G3 (25 mg, 0.03 mmol) under argon purging protection. The mixture is stirred at 30 °C for 6 h under argon purging protection. After the reaction is complete as determined by LC-MS, the reaction solution is filtered, the filtrate is concentrated, and the crude product is used directly in the next step.

[0213] LC-MS: m / z = 629.3 [M+1] + .

[0214] Preparation Example 4: Synthesis of IntB3:

[0215] Synthesis of IntB3-1:

[0216] Add (S)-3-bromo-2-(1-methoxyethyl)pyridine (90 g, 417 mmol) and THF (900 mL) to a 2 L three-necked flask. Under argon purging protection, lower the temperature to -30 to -20 °C. Then, control the temperature below -15 °C and add dropwise isopropyl magnesium chloride and lithium chloride solution (385 mL, 1.3 M in THF, 0.5 mol). After the addition is complete, maintain the temperature and stir the mixture for 2 h. Then, control the temperature below -15 °C and add dropwise 3,3-dimethyldihydro-2H-pyran-2,6(3H)-dione (56.4 g, 0.397 mol). After the addition is complete, maintain the temperature and stir the mixture for 20 h. After the LC-MS analysis showed that the reaction was basically complete, the mixture was quenched by adding water (250 mL), followed by adding glacial acetic acid (50 mL). The mixture was concentrated to approximately one-third of its original volume. Then, EA (500 mL) and water (250 mL) were added to the residue, and the mixture was stirred and separated. The aqueous phase was extracted twice more with EA (250 mL x 2). The combined organic phases were washed twice with saturated sodium chloride and concentrated to dryness. The crude product was used for the next step.

[0217] LC-MS: m / z = 280.1 [M+1] + .

[0218] Synthesis of IntB3-2:

[0219] Add the above-mentioned IntB3-1 (crude product, 397 mmol), 4-bromophenylhydrazine hydrochloride (65.2 g, 292 mmol), and water (395 mL) to a 2 L single-necked flask. Add concentrated H2SO4 (116.8 g, 1.168 mol) dropwise to the mixture under ice bath. After the addition is complete, heat the mixture to 100 °C under argon protection and stir for 48 h. After the reaction is complete as detected by LC-MS, cool the mixture and then add 20% NaOH solution dropwise under ice bath to adjust the pH to 5–6. A viscous solid precipitates from the system. Continue to add EA (250 mL) / PE (250 mL), stir and slurry at room temperature for 1 h, filter, and then slurry the filter cake again with EA (100 mL) / PE (250 mL) / water (200 mL) for 0.5 h. Filter, rinse the filter cake with water, dry under vacuum, and obtain an off-white solid (56 g, Y: 44.5%).

[0220] LC-MS: m / z = 431.1 [M+1] + .

[0221] Synthesis of IntB3-3:

[0222] IntB3-2 (56 g, 129.9 mmol), EtOH (560 mL), and DMF (1 mL) were added to a 2 L single-necked flask, followed by the dropwise addition of SOCl2 (23.2 g, 194.9 mmol) under ice bath conditions. After the addition was complete, the mixture was heated to 60 °C and stirred for 20 h. After the reaction was complete as detected by LC-MS, the mixture was cooled, and saturated sodium bicarbonate solution was added dropwise under ice bath conditions to adjust the pH to 7–8. A large amount of solid precipitated from the system. After stirring at room temperature for 1 h, the mixture was filtered, the filter cake was washed three times with water, dried under vacuum, and then dried to obtain a white solid (52 g, Y: 87.2%).

[0223] LC-MS: m / z = 459.1 [M+1] + .

[0224] Synthesis of IntB3-4:

[0225] IntB3-3 (25.5 g, 55.56 mmol), NMP (250 mL), and cesium carbonate (88.7 g, 272.1 mmol) were added to a 500 mL single-necked flask, followed by the dropwise addition of 2,2,2-trifluoroethyltrifluoromethanesulfonate (89.4 g, 385.2 mmol) under ice bath conditions. After the addition was complete, the mixture was heated to 50 °C under argon protection and stirred for 40 h. After the reaction was basically completed as detected by LC-MS, the mixture was quenched with water (500 mL), and then extracted twice with EA (250 mL * 2). The combined organic phases were washed with saturated sodium chloride solution, concentrated, and the residue was purified by column chromatography to obtain a yellow foamy solid product (32.5 g, Y: >100%).

[0226] LC-MS: m / z = 541.1 [M+1] + .

[0227] Synthesis of IntB3-5-P1:

[0228] To a 500 mL single-necked flask, add the above-mentioned compound IntB3-4 (32.5 g, overweight, 55.56 mmol) and EtOH (150 mL), followed by anhydrous calcium chloride (6.17 g, 55.56 mmol). After the mixture is stirred until dissolved at room temperature, add NaBH4 (5.25 g, 138.9 mmol) in portions and stir overnight at room temperature. LC-MS analysis showed that the reaction was incomplete, so anhydrous calcium chloride (6.17 g, 55.56 mmol) was added, followed by NaBH4 (2.63 g, 68.7 mmol) in portions, and the reaction was continued for 20 h with stirring at room temperature. After the LC-MS detection of the reaction was basically completed, the mixture was quenched by adding ice water (100 mL), concentrated to remove most of the EtOH, and the residue was added to EA (500 mL). After stirring at room temperature for 1 h, it was filtered through diatomaceous earth. The filter cake was washed twice with EA (100 mL). The filtrate was added to water (300 mL), stirred, separated, and the organic phase was washed with saturated sodium chloride solution, concentrated, and purified by column chromatography (EA:PE = 3:0 to 3:1 to 2:1 to 1:1 to 1:3 to DCM:MeOH = 25:1). The elution was first separated into the target configuration compound IntB3-5-P1 (11.9 g, Y: 42.9%) and the isomer IntB3-5-P2 (8.3 g, Y: 29.9%, eluted by DCM:MeOH system).

[0229] The above isomer IntB3-5-P2 (8.3 g, 16.63 mmol) was added to diphenyl ether (83 mL), and the mixture was stirred at 150 °C for 2 h under argon protection. The mixture was then purified by column chromatography to obtain the target configuration compound IntB3-5-P1 (4.2 g, Y: 50.6%).

[0230] LC-MS: m / z = 499.1 [M+1] + .

[0231] Synthesis of IntB3-6:

[0232] IntB3-5-P1 (17 g, 34.05 mmol) and THF (170 mL) were added to a 500 mL single-necked flask and stirred to dissolve. Then, HBPin (6.54 g, 51.07 mmol), B2Pin2 (17.3 g, 68.1 mmol), Me4Phen (643 mg, 2.72 mmol), and [Ir(OMe)(COD)]2 (452 ​​mg, 0.68 mmol) were added. After purging with argon, the reaction was carried out overnight at 50 °C. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and flash purified to obtain the target compound (15.2 g, Y: 82.3%).

[0233] LC-MS: m / z = 543.1 [M+1] + .

[0234] Synthesis of IntB3-7:

[0235] N-Cbz piperazine (40.62 g, 184.64 mmol), trimethyl phosphate (9.55 g, 68.2 mmol), and DCM (200 mL) were added to a 500 mL three-necked flask. Copper acetate (16.7 g, 91.96 mmol) was then added under ice bath conditions, followed by stirring with dry air at room temperature for 1 h. IntB3-6 (10.0 g, 18.44 mmol) was then added, and the reaction was stirred with dry air at room temperature for 48 h. After the reaction was basically complete as detected by LC-MS, the system was quenched with water (200 mL), followed by stirring with ammonia (10 mL) for 15 min, and then separated. The aqueous phase was extracted again with DCM (100 mL * 2), and the combined organic phases were washed twice with saturated sodium chloride solution. The pH was adjusted to 4–5 with water (100 mL) and saturated citric acid solution, and the mixture was stirred vigorously at room temperature for 15 min, followed by separation. The organic phase was washed once more with saturated sodium chloride solution and concentrated. The residue was purified by column chromatography (EA:PE = 2:0 to 2:1 to DCM:MeOH = 20:1) to give a white, foamy solid product (10.3 g, Y: 78%).

[0236] LC-MS: m / z = 717.2 [M+1] + .

[0237] Synthesize IntB3:

[0238] Add IntB3-7 (10 g, 13.96 mmol), boric acid (1.88 g, 20.94 mmol), Xphos (140 mg, 0.28 mmol), potassium tert-pentanoxide (4.15 g, 29.6 mmol), 2-methyltetrahydrofuran (180 mL), and MeOH (60 mL) to a 50 mL single-necked flask. Then add Xphos-Pd-G3 (117 mg, 0.14 mmol) under argon purging protection. Stir the mixture at 30 °C for 6 h under argon purging protection. After the reaction is complete as determined by LC-MS, filter the reaction mixture, concentrate the filtrate, and use the crude product directly in the next step.

[0239] LC-MS: m / z = 683.3 [M+1] + .

[0240] Preparation Example 5: Synthesis of IntB20:

[0241] Synthesis of IntB20-1:

[0242] In a 250 ml single-necked flask, (S)-3-bromo-2-(1-methoxyethyl)pyridine (11.65 g, 53.9 mmol), Diox (150 ml), potassium acetate (13.23 g, 135 mmol), 4A molecular sieve (11.7 g), and neopentyl glycol diboronate (30.46 g, 135 mmol) were added. After purging the mixture with argon, Pd(dppf)₂Cl₂ (1.97 g, 2.7 mmol) was added, and the mixture was heated to 90 °C and stirred for 20 h. After the reaction was completed, the mixture was filtered by LC-MS. The filter cake was washed with EA (50 ml * 3), and the filtrate was concentrated to dryness to obtain a black, gelatinous crude product, which was directly used in the next step.

[0243] LC-MS: m / z = 250.2 [M+1] + .

[0244] Synthesis of IntB20-2:

[0245] In a 500 ml single-necked flask, crude IntB20-1 (53.9 mmol), Diox (210 ml), toluene (70 ml), water (70 ml), potassium phosphate (26.6 g, 125 mmol), and IntC3 (25.6 g, 38.5 mmol) were added. After purging the mixture with argon, Pd(dppf)2Cl2 (1.45 g, 1.98 mmol) was added, and the mixture was heated to 70 °C and stirred for 20 h. After the reaction was completed, the mixture was filtered by LC-MS. The filter cake was washed with toluene (30 ml * 3), and the filtrate was concentrated to dryness. The residue was added to methyl tert-butyl ether (250 ml) / water (200 ml), stirred, separated, and the aqueous phase was extracted again with methyl tert-butyl ether (150 ml). The combined organic phases were washed with saturated sodium chloride solution, concentrated to dryness, and the residue was purified by column chromatography (PE:EA = 20:0 to 20:1 to 5:1) to give a brown oily product (24.7 g, Y: 95.3%).

[0246] LC-MS: m / z = 673.2 [M+1] + .

[0247] Synthesis of IntB20-3:

[0248] IntB20-2 (24.7 g, 36.7 mmol), DMF (250 mL), and cesium carbonate (35.9 g, 110 mmol) were added to a 500 mL single-necked flask, followed by dropwise addition of 2,2,2-trifluoroethyltrifluoromethanesulfonate (85 g, 367 mmol) under ice bath conditions. After the addition was complete, the mixture was stirred at room temperature for 40 h under argon protection. LC-MS analysis showed that the reaction was essentially complete. The mixture was then quenched with water (500 mL), followed by extraction twice with methyl tert-butyl ether (250 mL x 2). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a brown oily crude product, which was directly added to the next step.

[0249] LC-MS: m / z = 755.2 [M+1] + .

[0250] Synthesis of IntB20-4-P1:

[0251] Add the above-mentioned crude IntB20-3 (36.7 mmol), THF (370 mL), and TBAF (1 M, 184 mL) to a 1 L single-necked flask, and react overnight at 50 °C. After the reaction was confirmed to be complete by LC-MS, water (200 mL) was added to quench the reaction mixture, and then the solution was concentrated under reduced pressure to about one-third of the original volume. The residue was added to methyl tert-butyl ether (250 mL) / water (200 mL), stirred, separated, and the aqueous phase was extracted again with methyl tert-butyl ether (250 mL). The combined organic phases were washed twice with saturated sodium chloride solution (250 ml * 2), concentrated, and the residue was purified by column chromatography (EA:PE = 3:0 to 3:1 to 2:1 to 1:1 to 1:3 to DCM:MeOH = 25:1). The first elution was separated into the target configuration compound IntB20-4-P1 (6.1 g, Y: 32.1%) and the isomer IntB20-4-P2 (5.1 g, Y: 26.9%, eluted in DCM:MeOH system).

[0252] The above isomer IntB20-4-P2 (5.1 g, 9.86 mmol) was added to xylene (51 mL), and the mixture was stirred at 140 °C for 10 h under argon protection. The mixture was then purified by column chromatography to obtain the target configuration compound IntB20-4-P1 (2.8 g, Y: 54.9%).

[0253] LC-MS: m / z = 517.1 [M+1] + .

[0254] Synthesis of IntB20-5:

[0255] Add IntB20-4-P1 (8.9 g, 17.2 mmol) and THF (90 mL) to a 500 mL single-necked flask, stir to dissolve, and then add HBPin (2.42 g, 18.92 mmol). The mixture was reacted at 30 °C for 1 h under argon protection. Then, B2Pin2 (6.55 g, 25.8 mmol), 4,4′-di-tert-butyl-2,2′-bipyridine (369 mg, 1.376 mmol), and [Ir(OMe)(COD)]2 (226 mg, 0.34 mmol) were added. After argon purging protection, the mixture was stirred at 50 °C for 20 h. After the reaction was confirmed to be complete by LC-MS, the mixture was cooled in an ice bath, then quenched dropwise with water (180 mL), and extracted with methyl tert-butyl ether (200 mL). The mixture was separated, and the aqueous phase was extracted again with methyl tert-butyl ether (200 mL). The combined organic phases were washed with saturated sodium chloride solution (200 ml * 2), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude brown oily product (19.2 g). This crude product was directly added to the next step.

[0256] LC-MS: m / z = 561.1 [M+1] + (MS is the molecular weight of boric acid.)

[0257] Synthesis of IntB20-6:

[0258] N-Boc piperazine (8.0 g, 43 mmol), 2,2,6,6-tetramethylpiperidine (4.86 g, 34.4 mmol), and DCM (100 mL) were added to a 250 mL three-necked flask. Copper acetate (2.34 g, 12.9 mmol) was then added under ice bath conditions, followed by stirring with dry air at room temperature for 1 h. IntB20-5 (9.6 g, 8.6 mmol) was then added, and the reaction was stirred with dry air at room temperature for 48 h. After the reaction was basically complete as detected by LC-MS, the system was quenched with water (100 mL), followed by stirring with concentrated ammonia (50 mL) for 30 min, and then separated. The aqueous phase was extracted again with DCM (100 mL), and the combined organic phases were washed with concentrated ammonia (20 mL) / water (100 mL), and then washed twice with saturated sodium chloride solution. Add water (100 mL) and saturated citric acid solution to adjust the pH to 4-5. Stir at room temperature for 30 min, then separate the liquids. Wash the organic phase once more with saturated sodium chloride solution and concentrate. Purify the residue by column chromatography (EA:PE = 2:0 to 2:1 to DCM:MeOH = 20:1) to obtain a white, foamy solid product (3.4 g, Y: 56.4%).

[0259] LC-MS: m / z = 701.2 [M+1] + .

[0260] Synthesize IntB20:

[0261] Add IntB20-6 (1.7 g, 2.42 mmol), boric acid (326 mg, 3.63 mmol), Xphos (24 mg, 0.05 mmol), potassium tert-pentanoxide (711 mg, 5.08 mmol), 2-methyltetrahydrofuran (18 mL), and MeOH (6 mL) to a 50 mL single-necked flask. Then add Xphos-Pd-G3 (21 mg, 0.025 mmol) under argon purging protection. The mixture is stirred at 30 °C for 6 h under argon purging protection. After the reaction is complete as determined by LC-MS, the reaction solution is filtered, the filtrate is concentrated, and the crude product is used directly in the next step.

[0262] LC-MS: m / z = 667.3 [M+1] + .

[0263] Using different raw materials and referring to similar synthetic methods for IntB1, IntB2, IntB3, and IntB20, the target compounds IntB4-IntB26 in Table 1 were obtained.

[0264] Table 1

[0265] Preparation Example 6: Synthesis of IntC2:

[0266] Synthesis of IntC2-1:

[0267] 40 g of methyl 4-hydroxy-3,3-dimethylbutyrate (302.66 mmol), 26.8 g of imidazole (393.46 mmol), and 400 mL of DCM were added to a 2 L single-necked flask. A solution of 150 mL of DCM containing 87.35 g of TBDPSCl (317.79 mmol) was added dropwise at room temperature. After the addition was complete, the mixture was stirred at room temperature for 3 h. After the reaction was complete, the mixture was filtered by TLC / LC-MS. The filtrate was concentrated, and the residue was purified by column chromatography to obtain a colorless oily product (108 g, Y: 96%).

[0268] Synthesis of IntC2-2:

[0269] The above-mentioned compound IntC2-1 (108 g, 291.45 mmol), EtOH / H2O (400 mL / 400 mL), and KOH (32.7 g, 583 mmol) were added to a 1 L single-necked flask. The mixture was stirred at room temperature for 30 min, then refluxed for 2 h. After the reaction was completed as detected by LC-MS, the mixture was concentrated to about half its original volume, and then EA (500 mL) was added. The pH was adjusted to 3–4 with 2N HCl, stirred, and separated. The aqueous phase was extracted again with EA (500 mL). The combined organic phases were washed twice with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give a white solid product (101.3 g, Y: 97%).

[0270] Synthesis of IntC2-3:

[0271] The above-mentioned compound IntC2-2 (49 g, 137.53 mmol), DMF (1.06 mL, 13.75 mmol), and DCM (500 mL) were added to a 2 L single-necked flask. The mixture was kept under argon protection and cooled to -10 to -5 °C in an ice-salt bath. Then, a solution of oxalyl chloride (117 mL, 233.64 mmol) in DCM (100 mL) was slowly added dropwise. After the addition was complete, the mixture was stirred at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the mixture was concentrated to dryness to obtain a colorless oily crude product (52.7 g, Y: >100%).

[0272] Synthesis of IntC2-4:

[0273] Add the above compound IntC2-3 (52.7 g, crude product, 137.53 mmol) and DCM (200 mL) to a 1 L three-necked flask, and protect the mixture with argon gas. Cool to -15 to -10 °C in an ice-salt bath, then slowly add SnCl4 (140.5 mL of 1 M in DCM, 140.5 mmol). After the addition is complete, maintain the reaction temperature for 0.5 h. Then, slowly add a DCM (200 mL) solution of 5-bromo-1H-indole (27.55 g, 140.54 mmol) at -15 to -5 °C. After the addition is complete, continue to maintain the reaction temperature for 2 h. After the reaction was detected by LC-MS, the mixture was quenched by adding H2O (500 mL), stirred at room temperature for 30 min, filtered through diatomaceous earth, the filter cake was washed with DCM, the filtrate was separated, the aqueous phase was extracted with DCM again, the combined organic phases were washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, concentrated to dryness, and the residue was purified by column chromatography to obtain a yellow solid product (52 g, Y: 69%).

[0274] LC-MS: m / z = 534.1 [M+1] + .

[0275] Synthesis of IntC2-5:

[0276] The above-mentioned compound IntC2-4 (52 g, 97.27 mmol) and THF (520 mL) were added to a 1 L three-necked flask under argon protection. The mixture was cooled to -10 to 0 °C in an ice-salt bath, and then LiBH4 (146 mL 2 M in THF, 292 mmol) was slowly added dropwise. After the addition was complete, the mixture was kept at this temperature for 0.5 h. The temperature was then raised to 60 °C and the mixture was stirred for 40 h. After the reaction was basically completed by LC-MS, the mixture was quenched by slowly adding saturated ammonium chloride solution (100 mL) at room temperature. After stirring at room temperature for 1 h, saturated sodium chloride solution (250 mL) was added, and the mixture was stirred. The aqueous phase was separated and extracted with EA (250 mL). The organic phases were combined and concentrated, and the residue was purified by column chromatography to give a white solid product (40.1 g, Y: 74%).

[0277] LC-MS: m / z = 520.1 [M+1] + .

[0278] Synthesizing IntC2:

[0279] The above-mentioned compound IntC2-5 (25.1 g, 48.21 mmol), silver trifluoromethanesulfonate (13.627 g, 53.03 mmol), and THF (250 mL) were added to a 1 L single-necked flask, followed by the addition of elemental iodine (12.237 g, 48.21 mmol) in THF (50 mL). The mixture was stirred at room temperature for 3 h. After the reaction was confirmed to be complete by LC-MS, saturated sodium thiosulfate solution (100 mL) and water (100 mL) were added to the mixture, and the mixture was stirred at room temperature for 1 h. The mixture was then filtered through diatomaceous earth, the filter cake was washed with EA, the filtrate was separated, the aqueous phase was extracted again with EA (100 mL), the combined organic phases were washed with saturated sodium chloride solution, concentrated to dryness, and the residue was purified by column chromatography to give a light brown oily product (31.2 g, Y: 100%).

[0280] LC-MS: m / z = 646.1 [M+1] + .

[0281] Using different raw materials and referring to similar synthetic methods as in IntC2, the target compounds IntC3-IntC4 in Table 2 were obtained.

[0282] Table 2

[0283] Preparation Example 7: Synthesis of IntD1:

[0284] IntD1-1 (50 g, 146.2 mmol) and THF (500 mL) were added to a 1 L single-necked flask and stirred until dissolved. Then, cuprous iodide (2.78 g, 14.62 mmol), bis(triphenylphosphine)palladium dichloride (10.26 g, 14.62 mmol), triethylamine (29.6 g, 292.4 mmol), and IntD1-2 (22 g, 175.44 mmol) were added sequentially. After three purgings with argon gas, the reaction was carried out at room temperature for 3–5 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was filtered, the filtrate was concentrated, and purified by column chromatography to obtain a pale yellow oily compound, IntD1. LC-MS: m / z = 339 [M+1] + .

[0285] Using different raw materials and referring to similar synthetic methods in IntD1, the target compounds IntD2-IntD3 in Table 3 were obtained.

[0286] Table 3

[0287] Preparation Example 8: Synthesis of IntE1:

[0288] IntD1-1 (7 g, 20.47 mmol), K2CO3 (29.6 g, 292.4 mmol), Xantphos (1.18 g, 2.04 mmol), phosphorus dimethyl oxide (2.4 g, 30.77 mmol), and Diox (200 mL) were added to a 1 L single-necked flask. After purging with argon, Pd(OAc)2 (462 mg, 2.04 mmol) was added. The mixture was heated to 100 °C under argon protection and reacted for 20 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was filtered, the filtrate was concentrated, and purified by column chromatography to obtain a brown oily compound, IntE1. LC-MS: m / z = 292.0 [M+1] + .

[0289] Preparation Example 9: Synthesis of IntF1:

[0290] Synthesis of IntF1-1:

[0291] 2,4-Dibromo-1,3-thiazole (24.3 g, 100 mmol) and THF (300 mL) were added to a 1 L three-necked flask. The mixture was cooled to -20 to -10 °C under argon purging protection. Then, isopropyl magnesium bromide (100 mL, 1 M in THF, 100 mmol) was added dropwise, and the mixture was stirred and kept at this temperature for 1 h. Next, a THF (50 mL) solution of (4R)-4-formyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid tert-butyl ester (21.7 g, 94.64 mmol) was added dropwise below -10 °C. After the addition was complete, the mixture was stirred and kept at this temperature for 5 h. After the reaction was detected by LC-MS, the mixture was quenched with saturated ammonium chloride solution (500 mL), then extracted with EA (300 mL * 2), the combined organic phases were washed with saturated sodium chloride solution, concentrated, and the residue was purified by column chromatography (EA:PE = 10:0 to 10:1) to give a colorless oily product (33 g, yield: 88.7%).

[0292] LC-MS: m / z = 393[M+1] + .

[0293] Synthesis of IntF1-2:

[0294] The above-mentioned compound IntF1-1 (32.6 g, 82.95 mmol), EA (500 mL), and active MnO2 (36.1 g, 414.94 mmol) were added to a 1 L three-necked flask. The mixture was heated to 60 °C and stirred for 20 h under argon protection. After the reaction was completed, the mixture was cooled and filtered through diatomaceous earth. The filter cake was washed with EA, and the filtrate was concentrated to dryness to obtain a colorless oily product (33 g, yield: 100%).

[0295] LC-MS: m / z = 391 [M+1] + .

[0296] Synthesis of IntF1-3:

[0297] In a 2L three-necked flask, the above-mentioned compound IntF1-2 (30g, 76.72mmol) and THF (500mL) were added. The mixture was cooled to -10 to 0℃ under argon protection, and then DIBAL-H (115mL, 1M in Tol, 115mmol) was slowly added dropwise while maintaining the temperature below 0℃. After the addition was complete, the mixture was kept at -10 to 0℃ with stirring for 2 hours. After the reaction was complete as detected by LC-MS, the mixture was quenched with 500mL of ammonium chloride aqueous solution at 0℃. The mixture was filtered through diatomaceous earth, and the filter cake was washed with EA (300mL). The filtrate was separated, and the organic phase was washed again with saturated sodium chloride solution, concentrated, and the residue purified by column chromatography (EA:PE = 10:0 to 10:1) to obtain a colorless oily product (22g, yield: 73%).

[0298] LC-MS: m / z = 393[M+1] + .

[0299] Synthesis of IntF1-4:

[0300] In a 1L single-necked flask, the above-mentioned compound IntF1-3 (22 g, 55.98 mmol), MeOH (440 mL), and p-toluenesulfonic acid (0.96 g, 5.6 mmol) were added. After argon purging protection, the mixture was heated to 40 °C and stirred for 20 h. After the reaction was completed as detected by LC-MS, TEA (1 g) was added to the mixture, and then the solution was concentrated to dryness under reduced pressure. The crude product was used directly for the next step.

[0301] LC-MS: m / z = 353[M+1] + .

[0302] Synthesis of IntF1-5:

[0303] In a 1L single-necked flask, the above-mentioned compound IntF1-4 (30g, crude product, 55.98mmol), DCM (300mL), and TEA (17g, 168.3mmol) were added. The mixture was cooled to -5 to 0℃ in an ice-salt bath under argon purging protection, and then acetyl chloride (4.4g, 56.05mmol) in DCM (20mL) solution was slowly added dropwise. After the addition was complete, the mixture was allowed to rise naturally to room temperature, and then the reaction was continued with stirring for 20h. After the reaction was detected by LC-MS, the mixture was quenched with water (300mL), separated, and the aqueous phase was extracted again with DCM (100mL). The combined organic phases were washed with saturated sodium chloride solution, concentrated, and the residue was purified by column chromatography (EA:PE = 10:0 to 10:1 to 5:1) to give a light brown oily product (13.5g, yield: 61%).

[0304] LC-MS: m / z = 395 [M+1] + .

[0305] Synthesis of IntF1-6:

[0306] In a 1L single-necked flask, the above-mentioned compound IntF1-5 (12g, 30.38mmol), ACN (120mL), and DCM (120mL) were added. After purging with argon, thionyl chloride (9g, 75.63mmol) was added dropwise. The mixture was stirred at room temperature for 30min, then cooled to below -40℃, and a DCM / ACN (100mL / 100mL) solution of Py (9.6g, 121.52mmol) was added dropwise. After the addition was complete, the mixture was kept at -40℃ and stirred for 2h. After the reaction was completed by LC-MS, the mixture was diluted with DCM (200mL), then quenched with water (500mL), stirred, separated, and the organic phase was washed with 1N HCl (200mL), washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The resulting brown crude product was used directly in the next step.

[0307] LC-MS: m / z = 441[M+1] + .

[0308] Synthesis of IntF1-7:

[0309] In a 1L single-necked flask, the above-mentioned compound IntF1-6 (15g, crude product, 30.38mmol), ACN (120mL), and water (120mL) were added. The mixture was cooled to -5 to 0℃ in an ice-salt bath, followed by the addition of ruthenium trichloride hydrate (150mg, 0.69mmol), and then periodic acid (7.8g, 36.45mmol) in portions. The mixture was stirred and reacted at room temperature for 20h. After the reaction was completed as detected by LC-MS, EA (200mL) / water (200mL) was added to the mixture, stirred, and separated. The aqueous phase was then extracted with EA (100mL). The combined organic phases were washed three times with saturated sodium chloride solution, concentrated, and the residue was purified by column chromatography (EA:PE = 10:0 to 10:1 to 5:1) to give a white solid product (7.5g, yield: 54%).

[0310] LC-MS: m / z = 457 [M+1] + .

[0311] Synthesis of IntF1-8:

[0312] Add the above compound IntF1-7 (7g, 15.32mmol), ACN (100mL), and... to a 500mL single-necked flask.

[0313] 2-oxa-6-aza-spiro[3,3]heptane (2.28 g, 23.03 mmol) was mixed and stirred at 40 °C for 20 h under argon protection. After the reaction was completed, the mixture was concentrated by LC-MS. The residue was added to EA (200 mL) / water (100 mL), stirred, and separated. The aqueous phase was extracted again with EA (100 mL). The combined organic phases were washed with saturated sodium chloride solution and then concentrated to dryness to obtain a brown viscous product. The crude product was used directly in the next step.

[0314] LC-MS: m / z = 476.1 [M+1] + .

[0315] Synthesis of IntF1-9:

[0316] In a 500 mL single-necked flask, the above-mentioned compound IntF1-8 (10 g, crude product, 15.32 mmol), THF (50 mL), MeOH (50 mL), water (20 mL), and lithium hydroxide monohydrate (1.93 g, 45.95 mmol) were added. The mixture was stirred at room temperature for 2 h. After the reaction was completed by LC-MS, the pH of the mixture was adjusted to 6-7 with 2N HCl, and then concentrated to about one-third of the original volume. EA (100 mL) / water (50 mL) was added, the mixture was stirred, and the layers were separated. The aqueous phase was extracted again with EA (100 mL). The combined organic phases were washed with saturated sodium chloride solution, and then concentrated to dryness. The residue was flash purified to give a white solid product (3.2 g, yield: 48.1%).

[0317] LC-MS: m / z = 434.1 [M+1] + .

[0318] Synthesis of IntF1:

[0319] IntF1-9 (3.0 g, 6.91 mmol) and acetone (60 mL) were added to a 250 mL single-necked flask. The mixture was cooled to -5 to 0 °C in an ice-salt bath under argon protection, followed by the slow addition of Jones' reagent (2 mL). After the addition was complete, the mixture was allowed to rise naturally to room temperature and stirred for 4 h. After the reaction was confirmed by LC-MS, sodium thiosulfate aqueous solution was added to quench the reaction completely. The mixture was then extracted with DCM (100 mL * 3), the organic phases were combined and concentrated, the residue was flash purified, and lyophilized to give a pale green solid product (1.3 g, yield: 42%).

[0320] LC-MS: m / z = 446 [M-1] - .

[0321] Example 1 (1r,2R,3S)-N-((3S,4S,Z)-1 1 -Ethyl-1 7 -Fluorine-12 -(2-((S)-1-methoxyethyl)-5-(4-(oxecyclobutane-3-yl)piperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-3-(2-oxa-6-azaspiro[3.3]hept-6-yl)-1 1 H-8-Oza-6 2 6 3 Synthesis of diaza-2(4,2)-thiazo-1(5,3)-indolo-6(2,4)-bicyclo[3.1.1]heptane-4-yl)-2,3-dimethylcyclopropane-1-carboxamide (compound 1) and isomers 1A or 1B:

[0322] 1-1 Synthesis:

[0323] Add (S)-3-bromo-2-(1-methoxyethyl)pyridine (25 g, 115.7 mmol), 4A molecular sieve (25 g), and Diox (600 mL) to a 1 L single-necked flask, and stir until the starting materials are dissolved. Then add neopentyl glycol diboronate (65.3 g, 289.2 mmol), potassium acetate (28.4 g, 289.2 mmol), and Pd(dppf)Cl2 (8.5 g, 11.57 mmol). After purging with argon three times, react at 90 °C overnight. After the reaction is confirmed to be complete by LC-MS, cool to room temperature, filter the reaction solution through diatomaceous earth, wash the filter cake with DCM, and concentrate the filtrate to obtain crude compound 1-1 (94 g), which is used directly in the next step.

[0324] LC-MS: m / z = 182.2 [M-68+1] + .

[0325] Synthesis of 1-2:

[0326] Add compound 1-1 (94 g, 115.7 mmol crude) and IntC4 (85.5 g, 128.7 mmol) to a 2 L single-necked flask, dissolve in Dioxane (1 L) / H2O (200 mL), then add potassium carbonate (48 g, 347.1 mmol) and Pd(dppf)Cl2 (8.5 g, 11.57 mmol). After three purgings with argon gas, react at 85 °C for 48 h. After the reaction is complete as detected by LC-MS, filter the reaction solution through diatomaceous earth, wash the filter cake with EA, and concentrate the filtrate. Add water (500 mL) to the crude product, extract with EA (500 mL * 2), combine the organic phases, wash with saturated sodium chloride, concentrate the organic phase, and purify by column chromatography to obtain compound 1-2 (49.5 g, Y: 63.5%).

[0327] LC-MS: m / z = 673.2 [M+1] + .

[0328] Synthesis of 1-3:

[0329] Add compound 1-2 (41 g, 61 mmol) and DMF (600 mL) to a 1 L single-necked flask. After argon protection, cool to 0 °C, add Cs₂CO₃ (59.6 g, 183 mmol), stir at 0 °C for 0.5 h, then add iodoethane (28.5 g, 183 mmol) dropwise. After the addition is complete, allow the mixture to warm naturally overnight. After the reaction is confirmed to be complete by LC-MS, add ice water (1 L) to the reaction solution, extract with EA (500 mL * 2), combine the organic phases, wash with saturated sodium chloride, concentrate the organic phase, and purify by column chromatography to obtain compound 1-3 (34.8 g, Y: 81.3%).

[0330] LC-MS: m / z = 701.3 [M+1] + .

[0331] Synthesis of 1-4:

[0332] Add 1-3 (34.8 g, 49.61 mmol), THF (250 mL), and TBAF (1 M in THF, 265 mL) to a 1 L single-necked flask, and react overnight at 50 °C. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, and the residue was added to water (300 mL), extracted with EA (300 mL * 2), the organic phases were combined, washed twice with water and then with saturated sodium chloride, concentrated, and purified by column chromatography to obtain compounds 1-4 (10.5 g (target product) + 9 g (isomer), which can be separated by TLC).

[0333] LC-MS: m / z = 463.1 [M+1] + .

[0334] Synthesis of 1-5:

[0335] Compound 1-4 (20.7 g, 44.68 mmol) and n-heptane / THF (180 mL / 90 mL) were added to a 500 mL single-necked flask and stirred to dissolve. Then, HBPin (11.4 g, 89.36 mmol), B2Pin2 (34 g, 134.04 mmol), Me4Phen (2.1 g, 8.94 mmol), and [Ir(OMe)(COD)]2 (1.19 g, 1.79 mmol) were added. After purging with argon, the reaction was carried out overnight at 50 °C. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and flash purified to obtain compound 1-5 (19 g, Y: 72%).

[0336] LC-MS: m / z = 507.2 [M+1] + .

[0337] Synthesis of 1-6:

[0338] 1-(3-oxacyclobutyl)piperazine (2.04 g, 14.3 mmol), 4A molecular sieve (2 g), Py (566 mg, 7.15 mmol), TEA (724 mg, 7.15 mmol), and ultradry DCM (50 mL) were added to a 100 mL three-necked flask. The mixture was stirred at room temperature with air purging, and then compound 1-5 (843 mg, 1.43 mmol) was added. The mixture was allowed to react overnight at room temperature with the flask open. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and purified by column chromatography to obtain compound 1-6 (590 mg, Y: 68.3%).

[0339] LC-MS: m / z = 603.4 [M+1] + .

[0340] Synthesis of 1-7:

[0341] Add 1-6 (590 mg, 0.978 mmol), B2(OH)4 (135 mg, 1.5 mmol), KOPiv (294 mg, 2.1 mmol), Xphos (10 mg, 0.02 mmol), Xphos-Pd-G3 (8.5 mg, 0.01 mmol), and 2-MeTHF / MeOH (9 mL / 3 mL) to a 50 mL single-necked flask. After purging with argon, react at 30 °C. After the reaction is complete as detected by LC-MS, filter and concentrate the reaction solution to obtain crude product 1-7, which can be used directly in the next step.

[0342] LC-MS: m / z = 569.3 [M+1] + .

[0343] Synthesis of 1-8:

[0344] Crude compound 1-7 (0.978 mmol), IntF1 (438 mg, 0.978 mmol), K2CO3 (276 mg, 2 mmol), Pd(dtbpf)Cl2 (33 mg, 0.05 mmol), and Diox / H2O (10 mL / 3 mL) were added to a 50 mL single-necked flask. After purging with argon, the mixture was reacted at 75 °C. After the reaction was confirmed to be complete by LC-MS, the mixture was cooled to room temperature, filtered through a membrane, and flash purified to give compound 1-8 (662 mg, Y: 75.9%).

[0345] LC-MS: m / z = 892.4 [M+1] + .

[0346] Synthesis of 1-9:

[0347] Compounds 1-8 (508 mg, 0.57 mmol), IntA1 (217 mg, 0.627 mmol), and ACN / DCM (10 mL / 2 mL) were added to a 50 mL single-necked flask. After argon protection, the mixture was cooled to 0-5 °C, and NMI (234 mg, 2.85 mmol) and TCFH (240 mg, 0.855 mmol) were added sequentially. The mixture was reacted in an ice bath for 1 h. After the reaction was confirmed to be complete by LC-MS, water was added to the reaction solution, and the mixture was extracted three times with DCM. The organic phases were combined, concentrated, and flash purified to obtain compounds 1-9 (528 mg, Y: 83.8%).

[0348] LC-MS: m / z = 1106.5 [M+1] + .

[0349] Synthesis of 1-10:

[0350] Compound 1-9 (528 mg, 0.477 mmol) and MeOH (20 mL) were added to a 100 mL single-necked flask, followed by the addition of Pd(OH)₂ (400 mg). After purging with hydrogen, the mixture was reacted at room temperature for 3 h. After the reaction was confirmed to be complete by LC-MS, the mixture was filtered and concentrated to obtain compound 1-10 (480 mg, Y: 99%).

[0351] LC-MS: m / z = 1016.5 [M+1] + .

[0352] Synthesis of 1-11:

[0353] Add DIPEA (170 mg, 1.312 mmol), DMAP (27 mg, 0.219 mmol), HOBt (118 mg, 0.874 mmol), EDCI (252 mg, 1.312 mmol), and DCM (16 mL) to a 100 mL single-necked flask, stir at room temperature, and then add dropwise 4 mL of DCM solution containing 1-10 (480 mg, 0.472 mmol). Let the mixture react overnight at room temperature. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and flash-distilled to obtain compound 1-11 (193 mg, Y: 41%).

[0354] LC-MS: m / z = 998.5 [M+1] + .

[0355] Synthesis of 1-12:

[0356] Add compound 1-11 (181 mg, 0.193 mmol) and DCM (2 mL) to a 50 mL single-necked flask, stir at room temperature, then add TFA (2.5 mL) and react at room temperature for 1 h. After the reaction is complete as determined by LC-MS, concentrate the reaction solution, add DCM, adjust the pH to 7-8 with saturated sodium bicarbonate solution, extract three times with DCM, combine the organic phases, dry to anhydrous sodium sulfate, filter, and concentrate to obtain compound 1-12 (170 mg, Y: 98%).

[0357] LC-MS: m / z = 898.4 [M+1] + .

[0358] Synthesis of Compound 1:

[0359] Add 1-12 (90 mg, 0.10 mmol) and DCM (5 mL) to a 50 mL single-necked flask. After argon protection, cool to 0-5 °C. Then add NMM (20 mg, 0.20 mmol), (1r,2R,3S)-2,3-dimethylcyclopropane-1-carboxylic acid (14 mg, 0.12 mmol), HOBt (6 mg, 0.041 mmol), and EDCI (38 mg, 0.20 mmol) sequentially. Allow the mixture to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, concentrate the reaction solution and perform Flash purification to obtain compound 1. The compound was then purified by Pre-TLC (DCM:MeOH = 20:1 development) to obtain compounds 1A (51 mg, Y: 51.3%) and 1B (8 mg).

[0360] LC-MS: m / z = 994.5 [M+1] + .

[0361] Example 2 (1r,2R,3S)-N-((3S,4S,Z)-1 1 -Ethyl-1 6 -Fluoro-12-(2-((S)-1-methoxyethyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-3-(2-oxa-6-azaspiro[3.3]hept-6-yl)-1 1 H-8-Oza-6 2 6 3 Synthesis of -diaza-2(4,2)-thiazo-1(5,3)-indolo-6(2,4)-bicyclo[3.1.1]heptane-4-yl)-2,3-dimethylcyclopropane-1-carboxamide (compound 3) and isomers 3A, 3B, 3C, and 3D

[0362] Synthesis 3-1:

[0363] IntB1 (660 mg, 1.084 mmol), IntF1 (486 mg, 1.084 mmol), toluene (6 mL), dioxane (2 mL), and H2O (2 mL) were added to a 100 mL single-necked flask. Then, K3PO4 (574 mg, 2.711 mmol) and Pd(dppf)Cl2 (62 mg, 0.085 mmol) were added. After three purgings with argon gas, the mixture was heated to 70 °C and reacted for 12 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was directly concentrated and purified by column chromatography to obtain compound 3-1.

[0364] LC-MS: m / z = 850.4 [M+1] + .

[0365] Synthesis 3-2:

[0366] Compound 3-1 (646 mg, 0.760 mmol), IntA1 hydrochloride (145 mg, 0.760 mmol), and DMF (5 mL) were added to a 25 mL single-necked flask. Then, DIPEA (196 mg, 1.52 mmol) and HATU (346 mg, 0.912 mmol) were added, and the mixture was stirred at room temperature for 4 h. After the reaction was confirmed to be complete by LC-MS, saturated brine was added, and the mixture was extracted three times with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 3-2.

[0367] LC-MS: m / z = 1064.5 [M+1] + .

[0368] Synthesis 3-3:

[0369] Add 3-2 (670 mg, 0.63 mmol) to a 50 mL single-necked flask, dissolved in THF (5 mL), MeOH (5 mL), and H2O (3 mL). Then add lithium hydroxide monohydrate (80 mg, 1.90 mmol) and stir at room temperature for 2 h. After the reaction is complete as detected by LC-MS, adjust the pH of the reaction solution to 5-6 with 1 M hydrochloric acid, add a small amount of saturated saline, extract three times with EA, combine the organic phases, concentrate, flash-purify the residue, and lyophilize to obtain compound 3-3.

[0370] LC-MS: m / z = 974.5 [M+1] + .

[0371] Synthesis 3-4:

[0372] Compound 3-3 (433 mg, 0.445 mmol) and ACN (10 mL) were added to a 50 mL single-necked flask, followed by N,N,N',N'-tetramethylchloromethamine hexafluorophosphate (3.75 g, 13.35 mmol) and N-methylimidazole (1.1 g, 13.35 mmol). The mixture was stirred at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was directly concentrated, and the residue was flash purified to obtain compound 3-4.

[0373] LC-MS: m / z = 956.5 [M+1] + .

[0374] Synthesize 3-5:

[0375] Add 3-4 (267 mg, 0.279 mmol) and DCM (5 mL) to a 25 mL single-necked flask, then add TFA (637 mg, 5.588 mmol), and stir at room temperature for 3 h. After the reaction is complete as determined by LC-MS, concentrate the reaction solution, add the residue to DCM (20 mL) and saturated sodium bicarbonate solution (10 mL), stir, separate the layers, and extract the aqueous phase again with DCM (20 mL). Combine the organic phases, wash with saturated sodium chloride solution, dry to anhydrous sodium sulfate, filter, and concentrate to dryness to give compound 3-5.

[0376] LC-MS: m / z = 856.4 [M+1] + .

[0377] Synthesized compound 3:

[0378] 3-5 (167 mg, 0.195 mmol), (1r,2R,3S)-2,3-dimethylcyclopropyl-1-carboxylic acid (27 mg, 0.237 mmol), and DMF (5 mL) were added to a 25 mL single-necked flask. Then, DIPEA (50 mg, 0.390 mmol) and HATU (89 mg, 0.230 mmol) were added, and the mixture was stirred at room temperature for 2 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was directly purified by Flash chromatography to obtain compound 3. Compound 3 was purified twice by pre-TLC (DCM:MeOH = 20:1) to obtain compounds 3A (42 mg), 3B (40 mg), 3C (6 mg), and 3D (6 mg), respectively.

[0379] LC-MS: m / z = 952.5 [M+1] + .

[0380] Example 3 (1r,2R,3S)-N-((4S,Z)-1 2-(5-(4-(2-(aminooxy)acetyl)piperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-1 1 -Ethyl-10,10-dimethyl-5,7-dioxo-1 1 H-8-Oza-6 2 6 3 Synthesis of 12-diaza-2(4,2)-thiazo-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptane-4-yl)-2,3-dimethylcyclopropane-1-carboxamide (compound 12):

[0381] Synthesis of 12-1:

[0382] Benzyl-1-piperazine carbonate (29.86 g, 135.55 mmol), 4A molecular sieve (50 g), Py (5.36 g, 67.78 mmol), TEA (6.85 g, 67.78 mmol), and ultra-dry DCM (300 mL) were added to a 500 mL three-necked flask. The mixture was stirred at room temperature with air aeration. Then (S)-3-(5-bromo-1-ethyl-2-(2-(1-methoxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborhecyclopentan-2-yl)pyridin-3-yl)-1H-indol-3-yl)-2,2-dimethylprop-1-ol (7.74 g, 13.55 mmol, prepared according to the method of Example 1, yielding an axially chiral single intermediate) was added. The mixture was reacted overnight at room temperature with air aeration. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and purified by column chromatography to obtain compound 12-1 (5.8 g, Y: 64%).

[0383] LC-MS: m / z = 663.3 [M+1] + .

[0384] Synthesis of 12-2:

[0385] Add 12-1 (5.8 g, 8.74 mmol), B2(OH)4 (1.18 g, 13.11 mmol), KOPiv (2.57 g, 18.35 mmol), Xphos (83 mg, 0.175 mmol), Xphos-Pd-G3 (74 mg, 0.087 mmol), and 2-MeTHF / MeOH (90 mL / 30 mL) to a 250 mL single-necked flask. After purging with argon, react at 30 °C. After the reaction was confirmed to be complete by LC-MS, filter and concentrate the reaction solution to obtain crude 12-2 (8.6 g), which was used directly in the next step.

[0386] LC-MS: m / z = 629.4 [M+1] + .

[0387] Synthesis of 12-3:

[0388] Crude product 12-2 (8.74 mmol), methyl (S)-2-(Boc-amino)-3-(4-bromo-2-thiazolyl)propionate (3.35 g, 9.18 mmol), K2CO3 (2.42 g, 17.48 mmol), Pd(dtbpf)Cl2 (285 mg, 0.437 mmol), and Diox / H2O (100 mL / 30 mL) were added to a 250 mL single-necked flask. After purging with argon, the reaction was carried out at 75 °C. After the reaction was confirmed to be complete by LC-MS, the reaction solution 12-3 was used directly for the next step.

[0389] LC-MS: m / z = 869.4 [M+1] + .

[0390] Synthesis of 12-4:

[0391] LiOH·H2O (1.84 g, 43.7 mmol) was added to reaction solution 12-3 and the reaction was carried out at room temperature. After the reaction was confirmed to be complete by LC-MS, the pH was adjusted to 6-7 with saturated citric acid solution, and then concentrated to half of the solvent. After flash purification and lyophilization, compound 12-4 (6.28 g, Y: 84%) was obtained.

[0392] LC-MS: m / z = 855.4 [M+1] + .

[0393] Synthesis of 12-5:

[0394] 12-4 (9.02 g, 10.55 mmol), IntA1 (4.02 g, 11.60 mmol), and ACN / DCM (250 mL / 50 mL) were added to a 500 mL single-necked flask. After argon protection, the mixture was cooled to 0-5 °C, and NMI (4.33 g, 52.75 mmol) and TCFH (4.44 g, 15.83 mmol) were added sequentially. The mixture was reacted in an ice bath for 1 h. After the reaction was confirmed to be complete by LC-MS, water was added to the reaction solution, and the mixture was extracted three times with DCM. The organic phases were combined, concentrated, and purified by column chromatography to obtain compound 12-5 (10.15 g, Y: 90%).

[0395] LC-MS: m / z = 1069.5 [M+1] + .

[0396] Synthesis of 12-6:

[0397] 12-5 (10.15 g, 9.49 mmol) and THF / H2O (100 mL / 20 mL) were added to a 250 mL single-necked flask and cooled to 0-5 °C. Then, LiOH·H2O (599 mg, 14.24 mmol) was added, and the mixture was reacted at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the pH was adjusted to 6-7 with saturated citric acid solution, THF was removed by concentration, and the mixture was flash purified to obtain compound 12-6 (8.86 g, Y: 95%).

[0398] LC-MS: m / z = 979.4 [M+1] + .

[0399] Synthesis of 12-7:

[0400] DIPEA (2.24 g, 17.36 mmol), DMAP (530 mg, 4.34 mmol), HOBt (2.35 g, 17.36 mmol), EDCI (5 g, 26.04 mmol), and DCM (350 mL) were added to a 500 mL single-necked flask and stirred at room temperature. Then, 12-6 (8.5 g, 8.68 mmol) of DCM (100 mL) solution was slowly added dropwise to the system. After the addition was complete, the reaction was allowed to proceed overnight at room temperature. After the reaction was confirmed to be complete by LC-MS, water (200 mL) was added to the reaction solution, and the mixture was extracted three times with DCM. The organic phases were combined, concentrated, and purified by column chromatography to obtain the compound (4.21 g, Y: 50.5%).

[0401] LC-MS: m / z = 961.5 [M+1] + .

[0402] Isomers were separated by prep-HPLC. The method and results are as follows:

[0403] Instrument: Agilent, Prep-LC: 1290InfinityII;

[0404] Column: Welch Xtimate C18:30*150mm,5um

[0405] Wave length: 254nm / 214nm

[0406] phase A: H2O (0.1% FA); phase B: ACN

[0407] Gradient:

[0408] Table 4

[0409] RT: 12-7 (target product): 12.6 min, 12-7 iso: 11.7 min (mixture of isomers)

[0410] Synthesis of 12-8:

[0411] 12-7 (4.21 g, 4.37 mmol) and DCM (53 mL) were added to a 250 mL single-necked flask and stirred at room temperature. Then, TFA (53 mL) was added to the system and the mixture was reacted at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, DCM was added, and the pH was adjusted to 7-8 with saturated sodium bicarbonate solution. The mixture was extracted four times with DCM, and the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 12-8 (3.79 g, Y: 100%).

[0412] LC-MS: m / z = 861.4 [M+1] + .

[0413] Synthesis of 12-9:

[0414] 12-8 (2.79 g, 3.24 mmol) and DCM (50 mL) were added to a 100 mL single-necked flask. After argon protection, the mixture was cooled to 0-5 °C, and then NMM (983 mg, 9.72 mmol), (1r,2R,3S)-2,3-dimethylcyclopropane-1-carboxylic acid (444 mg, 3.89 mmol), HOBt (88 mg, 0.648 mmol), and EDCI (1.12 g, 5.83 mmol) were added sequentially. The mixture was allowed to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and flash purified to obtain compound 12-9 (2.8 g, Y: 90%).

[0415] LC-MS: m / z = 957.5 [M+1] + .

[0416] Synthesis of 12-10:

[0417] 12-9 (2.8 g, 2.925 mmol) and MeOH (150 mL) were added to a 250 mL single-necked flask, followed by the addition of Pd(OH)₂ (2.8 g). After purging with hydrogen, the mixture was reacted at room temperature for 3 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was filtered and concentrated to dryness to obtain compound 12-10 (2.4 g, Y: 100%).

[0418] LC-MS: m / z = 823.4 [M+1] + .

[0419] Synthesis of compound 12:

[0420] 12-10 (50 mg, 0.061 mmol) and DCM (2 mL) were added to a 25 mL single-necked flask. Under argon protection, NMM (19 mg, 0.183 mmol), 2-(aminooxy)acetic acid (6 mg, 0.066 mmol), HOBt (2 mg, 0.012 mmol), and EDCI (21 mg, 0.11 mmol) were added sequentially, and the reaction was allowed to proceed at room temperature. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, purified first by Flash LC, and then purified by Pre-TLC to obtain compound 12 (16 mg, Y: 29.3%).

[0421] LC-MS: m / z = 896.5 [M+1].

[0422] Example 4N-((4S,Z)-1 2 -(5-(4-(L-valine)piperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-1 1 -Ethyl-10,10-dimethyl-5,7-dioxo-1 1 H-8-Oza-6 2 6 3 Synthesis of 24-diaza-2(4,2)-thiazo-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptane-1-carboxamide (compound 24):

[0423] Synthesis of 24-1:

[0424] Add 12-8 (430 mg, 0.50 mmol / 3.24 mmol) and DCM (10 mL) to a 100 mL single-necked flask. After argon protection, cool to 0-5 °C, then add NMM (152 mg, 1.50 mmol), bicyclo[2.2.1]heptane-1-carboxylic acid (84 mg, 0.60 mmol), HOBt (135 mg, 1.0 mmol), and EDCI (172 mg, 0.90 mmol) sequentially. Allow the mixture to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, concentrate the reaction solution and flash purify to obtain compound 24-1 (440 mg, Y: 89.5%).

[0425] LC-MS: m / z = 983.5 [M+1] + .

[0426] Synthesis of 24-2:

[0427] 24-1 (440 mg, 0.448 mmol) and MeOH (15 mL) were added to a 250 mL single-necked flask, followed by the addition of Pd(OH)2 (440 mg). After purging with hydrogen, the mixture was reacted at room temperature for 3 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was filtered and concentrated to dryness to obtain compound 24-2 (367 mg, Y: 96.5%).

[0428] LC-MS: m / z = 849.4 [M+1] + .

[0429] Synthesis of 24-3:

[0430] 24-2 (50 mg, 0.059 mmol) and DCM (2 mL) were added to a 25 mL single-necked flask. Under argon protection, NMM (19 mg, 0.183 mmol), N-Boc-L-valine (14 mg, 0.065 mmol), HOBt (2 mg, 0.012 mmol), and EDCI (21 mg, 0.11 mmol) were added sequentially, and the reaction was carried out at room temperature. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, first purified by Flash, and then purified by Pre-TLC to obtain compound 24-3 (36 mg, Y: 58.2%, bridged ring chiral isomer removed).

[0431] LC-MS: m / z = 1048.5 [M+1].

[0432] Synthesis of compound 24:

[0433] Add 24-3 (30 mg, 0.029 mmol) and DCM (3 mL) to a 25 mL single-necked flask, stir at room temperature, then add TFA (1 mL) to the system and react at room temperature for 1 h. After the reaction is complete as detected by LC-MS, concentrate the reaction solution, purify the residue by alkaline Flash purification, and freeze-dry to obtain compound 24 (17 mg, Y: 61.8%).

[0434] LC-MS: m / z = 948.5 [M+1].

[0435] Example 5N-((4S,Z)-1 2 -(5-(4-(L-leucyl)piperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-1 1 -(2,2,2-trifluoroethyl)-1 1 H-8-Oza-6 2 6 3Synthesis of -diaza-2(4,2)-thiazo-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptane-4-yl)bicyclo[4.1.0]heptane-7-carboxamide (compound 64):

[0436] Synthesis of 64-1:

[0437] Add IntB3 (22.5 g, crude product, 22.33 mmol), (S)-2-(Boc-amino)-3-(4-bromo-2-thiazolyl)propionate (8.563 g, 23.45 mmol), K2CO3 (6.172 g, 44.66 mmol), Pd(dtbpf)Cl2 (728 mg, 1.11 mmol), and Diox / H2O (330 mL / 100 mL) to a 1 L single-necked flask. After purging with argon, the mixture was heated to 75 °C and reacted for 20 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was used directly for the next step.

[0438] LC-MS: m / z = 923.4 [M+1] + .

[0439] Synthesis of 64-2:

[0440] LiOH·H₂O (4.69 g, 111.67 mmol) was added to the above reaction solution 64-1, and the mixture was stirred at room temperature for 2 h. LC-MS analysis showed that the reaction was incomplete, so LiOH·H₂O (4.69 g, 111.67 mmol) was added again, and the reaction was stirred for another 4 h. After the reaction was complete as determined by LC-MS analysis, the pH of the mixture was adjusted to 6-7 with citric acid solution, then concentrated to a small amount. The residue was flash purified, lyophilized, and a brown solid product (17.6 g, Y: 83%) was obtained.

[0441] LC-MS: m / z = 909.4 [M+1] + .

[0442] Synthesis of 64-3:

[0443] Add 64-2 (12.8 g, 14.08 mmol), IntA1 (5.36 g, 15.49 mmol), and ACN / DCM (300 mL / 60 mL) to a 500 mL single-necked flask. After argon protection, cool to 0-5 °C, then add NMI (6.935 g, 84.48 mmol) and TCFH (5.926 g, 21.12 mmol) sequentially. React in an ice bath for 1 h. After the reaction is confirmed to be complete by LC-MS, add water to the reaction solution, extract three times with DCM, combine the organic phases, concentrate, and obtain a crude yellow-brown compound (17.2 g, Y: 85%). This crude product is used directly in the next step.

[0444] LC-MS: m / z = 1123.5 [M+1] + .

[0445] Synthesis of 64-4:

[0446] Compound 64-3 (17.2 g, 16.43 mmol), LiOH·H2O (1.035 g, 24.64 mmol), THF (150 mL), and water (30 mL) were added to a 500 mL single-necked flask and reacted at room temperature for 2 h. After the reaction was confirmed to be complete by LC-MS, the pH was adjusted to 6–7 with citric acid solution, and then the THF was removed by concentration. The residue was purified by flash filtration and lyophilized to obtain the compound (16.8 g, Y: 99%).

[0447] LC-MS: m / z = 1033.4 [M+1] + .

[0448] Synthesis of 64-5:

[0449] DIPEA (5.917 g, 45.78 mmol), DMAP (932 mg, 7.63 mmol), HOBt (4.124 g, 30.52 mmol), EDCI (8.776 g, 45.78 mmol), and DCM (600 mL) were added to a 1 L single-necked flask. The mixture was stirred for 10 min under argon protection, followed by slow dropwise addition of 150 mL of DCM solution (64-4, 15.767 g, 15.266 mmol). After the addition was complete, the mixture was stirred at room temperature for 20 h. After the reaction was complete as detected by LC-MS, the mixture was concentrated, and the residue was Flash purified. The target fraction was adjusted to alkali with saturated sodium bicarbonate, extracted with EA, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain the target product (8.2 g, Y: 50%, HPLC showed ~20% isomers).

[0450] LC-MS: m / z = 1015.4 [M+1] + .

[0451] Isomers were separated by prep-HPLC. The method and results are as follows:

[0452] Instrument: Agilent, Prep-LC: 1290InfinityII;

[0453] Column: Welch Xtimate C18:30*150mm,5um

[0454] Wave length: 254nm / 214nm

[0455] phase A: H2O (0.1% FA); phase B: ACN

[0456] Gradient:

[0457] Table 5

[0458] RT: 64-5 (target product): 14.2 min, 64-5iso: 12.9 min (mixture of isomers)

[0459] Synthesis of 64-6:

[0460] 64-5 (8.2 g, 8.08 mmol) and DCM (82 mL) were added to a 500 mL single-necked flask and stirred at room temperature. Then, TFA (82 mL) was added to the system, and the reaction was allowed to proceed at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, DCM was added, and the pH was adjusted to 7-8 with saturated sodium bicarbonate solution. The mixture was extracted three times with DCM, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the compound (7.028 g, Y: 95%).

[0461] LC-MS: m / z = 915.4 [M+1] + .

[0462] Synthesis of 64-7:

[0463] Add 64-6 (3.5 g, 3.825 mmol) and DCM (90 mL) to a 250 mL single-necked flask. After argon protection, cool to 0-5 °C, then add NMM (1.161 g, 11.475 mmol), bicyclo[4.1.0]heptane-7-carboxylic acid (589 mg, 4.207 mmol), HOBt (103 mg, 0.765 mmol), and EDCI (1.32 g, 6.885 mmol). Allow the mixture to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, concentrate the reaction solution, purify it using Flash, and freeze-dry to obtain compound 64-7 (3.934 g, Y: 99%, LC-MS showed ~20% isomers).

[0464] LC-MS: m / z = 1037.5 [M+1] + .

[0465] Synthesis of 64-8:

[0466] 64-7 (3.934 g, 3.793 mmol) and MeOH (100 mL) were added to a 250 mL single-necked flask, followed by the addition of 20% Pd(OH)2 / C (2.4 g). After hydrogen purging, the mixture was reacted at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a white solid product (3.151 g, Y: 92%).

[0467] LC-MS: m / z = 903.4 [M+1] + .

[0468] Synthesis of 64-9:

[0469] 64-8 (400 mg, 0.443 mmol) and DCM (10 mL) were added to a 50 mL single-necked flask. After argon protection, the mixture was cooled to 0-5 °C, and NMM (140 mg, 1.329 mmol), (tert-butyloxycarbonyl)-L-leucine (123 mg, 0.532 mmol), HOBt (12 mg, 0.089 mmol), and EDCI (153 mg, 0.797 mmol) were added sequentially. The mixture was allowed to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, purified by flash filtration, and lyophilized to obtain compound 64-9 (413 mg, Y: 84%).

[0470] LC-MS: m / z = 1116.5 [M+1] + .

[0471] Synthesis of 64:

[0472] 64-9 (413 mg, 0.37 mmol) and DCM (10 mL) were added to a 50 mL single-necked flask and stirred at room temperature. Then, TFA (1.5 mL) was added to the system and the mixture was reacted at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, DCM was added, and the pH was adjusted to 7-8 with saturated sodium bicarbonate solution. The mixture was extracted three times with DCM, the organic phases were combined, concentrated, and the residue was purified by Flash purification (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column). The residue was lyophilized to give the compound (335 mg, Y: 89%).

[0473] LC-MS: m / z = 1015.6 [M+1] + .

[0474] Example 6N-((6) 4 S,4S,Z)-1 2 -(5-(4-((S)-2-hydroxy-2-phenylacetyl)piperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-1 1-(2,2,2-trifluoroethyl)-1 1 H-8-Oza-6 2 6 3 Synthesis of 116-diaza-2(4,2)-thiazo-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptane-4-yl)bicyclo[4.1.0]heptane-7-carboxamide (compound 116):

[0475] Synthesis of 116:

[0476] Add 64-8 (30 mg, 0.033 mmol) and DCM (3 mL) to a 25 mL single-necked flask. After argon protection, cool to 0-5 °C, then add NMM (10 mg, 0.99 mmol), (S)-2-hydroxy-2-phenylacetic acid (7.6 mg, 0.05 mmol), HOBt (1 mg, 0.007 mmol), and EDCI (11 mg, 0.06 mmol) sequentially. Allow the mixture to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, and the residue was purified by prep-HPLC to obtain compound 116 (20 mg).

[0477] LC-MS: m / z = 1037.5 [M+1] + .

[0478] The Prep-HPLC method is as follows:

[0479] Sample name: Compound 116-Method

[0480] Instrument: Agilent 1290infinity II

[0481] Column: Xtimate C18 30*150mm,5um

[0482] Wave length: 214nm / 254nm

[0483] Phase A: H2O (0.1% FA)

[0484] phase B: ACN

[0485] Gradient:

[0486] Table 6

[0487] Example 7 (1r,2R,3S)-N-((6 4 S,4S,Z)-1 2-(2-((S)-1-methoxyethyl)-5-(4-((S)-4-methylmorpholin-2-carbonyl)piperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-1 1 -(2,2,2-trifluoroethyl)-1 1 H-8-Oza-6 2 6 3 Synthesis of 168-diaza-2(4,2)-thiazo-1(5,3)-indolo-6(2,4)-bicyclo[3.1.1]heptane-4-yl)-2,3-dimethylcyclopropane-1-carboxamide (compound 168):

[0488] Synthesis of 168-1:

[0489] 64-6 (1.2 g, 1.31 mmol) and DCM (60 mL) were added to a 250 mL single-necked flask. After argon protection, the mixture was cooled to 0–5 °C. NMM (397 mg, 3.93 mmol), (1r,2R,3S)-2,3-dimethylcyclopropane-1-carboxylic acid (194 mg, 1.70 mmol), HOBt (35 mg, 0.262 mmol), and EDCI (452 ​​mg, 2.36 mmol) were added sequentially. The mixture was allowed to react overnight in an ice bath. After LC-MS analysis to confirm complete reaction, the reaction solution was concentrated, purified by flash filtration, and lyophilized to obtain the compound (1.22 g, Y: 92%, LC-MS showed ~20% isomers). This compound was further purified by prep-HPLC according to method 12-7 to obtain the target product 168-1 (770 mg, Y: 63.1%), which was free of isomers.

[0490] LC-MS: m / z = 1011.4 [M+1] + .

[0491] Synthesis of 168-2:

[0492] 168-1 (770 mg, 0.762 mmol) and MeOH (20 mL) were added to a 100 mL single-necked flask, followed by the addition of 20% Pd(OH)2 / C (700 mg). After purging with hydrogen, the mixture was reacted at room temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a white solid product (640 mg, Y: 95.8%).

[0493] LC-MS: m / z = 877.4 [M+1] + .

[0494] Synthesis of 168-3:

[0495] 168-2 (60 mg, 0.0684 mmol) and DCM (5 mL) were added to a 25 mL single-necked flask. After argon protection, the mixture was cooled to 0-5 °C, and NMM (21 mg, 0.2052 mmol), (S)-4-(tert-butyloxycarbonyl)morpholine-2-carboxylic acid (21 mg, 0.0889 mmol), HOBt (2 mg, 0.0137 mmol), and EDCI (24 mg, 0.123 mmol) were added sequentially. The mixture was allowed to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and then purified by Flash (0.1% TFA aqueous solution / acetonitrile, through a reversed-phase column), and lyophilized to obtain compound 168-3 (65 mg, Y: 87%).

[0496] LC-MS: m / z = 1090.5 [M+1] + .

[0497] Synthesis of 168-4:

[0498] Add 168-3 (65 mg, 0.06 mmol) and DCM (2 mL) to a 50 mL single-necked flask, stir at room temperature, then add TFA (2 mL) to the system and react at room temperature for 1 h. After the reaction is complete as detected by LC-MS, concentrate the reaction solution, add DCM, adjust the pH to 7-8 with saturated sodium bicarbonate solution, extract three times with DCM, combine the organic phases, concentrate, and purify the residue by flash (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column), lyophilize to obtain the compound (55 mg).

[0499] LC-MS: m / z = 990.4 [M+1] + .

[0500] Synthesis of 168:

[0501] 168-4 (45 mg, 0.0454 mmol), MeOH (3 mL), AcOH (1 drop), and paraformaldehyde (7 mg, 0.227 mmol) were added to a 25 mL single-necked flask, and the mixture was stirred at room temperature for 1 h. Then, NaBH3CN (9 mg, 0.136 mmol) was added, and the mixture was heated to 40 °C and stirred for 20 h. After the reaction was complete as detected by LC-MS, the mixture was concentrated, and the residue was purified by Flash chromatography (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column), lyophilized, and the compound (44 mg) was obtained.

[0502] LC-MS: m / z = 1004.5 [M+1] + .

[0503] Example 8N-((6) 4 S,4S,Z)-1 2-(2-((S)-1-methoxyethyl)-5-(4-((S)-4-methylmorpholin-2-carbonyl)piperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-1 1 -(2,2,2-trifluoroethyl)-1 1 H-8-Oza-6 2 6 3 Synthesis of 189: 2-diaza-2(4,2)-thiazolyl-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptan-1 / 2-undecane-4-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide (compound 189):

[0504] Synthesis of 189-1:

[0505] Add 64-6 (52 mg, 0.0568 mmol, preparatively purified to remove isomers) and DCM (3 mL) to a 25 mL single-necked flask. After argon protection, cool to 0-5 °C, then add NMM (17 mg, 0.17 mmol), 3-oxabicyclo[3.1.0]hexane-6-carboxylic acid (9.5 mg, 0.074 mmol), HOBt (1.5 mg, 0.011 mmol), and EDCI (20 mg, 0.102 mmol) sequentially. React overnight at an ice bath. After the reaction is confirmed to be complete by LC-MS, concentrate the reaction solution, purify by flash, and lyophilize to obtain the compound (53 mg, Y: 94%).

[0506] LC-MS: m / z = 1025.4 [M+1] + .

[0507] Synthesis of 189-2:

[0508] Add 189-1 (53 mg, 0.0517 mmol) and MeOH (5 mL) to a 50 mL single-necked flask, then add 20% Pd(OH)2 / C (20 mg). After purging with hydrogen, react at room temperature for 1 h. After the reaction is complete as detected by LC-MS, filter through diatomaceous earth, concentrate the filtrate to obtain a white solid product (47 mg, Y: 100%).

[0509] LC-MS: m / z = 891.4 [M+1] + .

[0510] Synthesis of 189-3:

[0511] 189-2 (42 mg, 0.047 mmol) and DCM (3 mL) were added to a 25 mL single-necked flask. After argon protection, the mixture was cooled to 0–5 °C, and NMM (14 mg, 0.141 mmol), (S)-4-(tert-butyloxycarbonyl)morpholine-2-carboxylic acid (13 mg, 0.057 mmol), HOBt (1.3 mg, 0.009 mmol), and EDCI (16 mg, 0.085 mmol) were added sequentially. The mixture was allowed to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and then purified by Flash (0.1% TFA aqueous solution / acetonitrile, through a reversed-phase column), and lyophilized to obtain compound 189-3 (48 mg, Y: 92%).

[0512] LC-MS: m / z = 1104.5 [M+1] + .

[0513] Synthesis of 189-4:

[0514] Add 189-3 (48 mg, 0.043 mmol) and DCM (2 mL) to a 25 mL single-necked flask, stir at room temperature, then add TFA (0.5 mL) to the system and react at room temperature for 1 h. After the reaction is complete as detected by LC-MS, concentrate the reaction solution, add DCM, adjust the pH to 7-8 with saturated sodium bicarbonate solution, extract three times with DCM, combine the organic phases, concentrate, and purify the residue by Flash purification (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column), lyophilize, and give the compound (44 mg, Y: 100%).

[0515] LC-MS: m / z = 1004.4 [M+1] + .

[0516] Synthesis of 189:

[0517] 189-4 (44 mg, 0.044 mmol), MeOH (3 mL), AcOH (1 drop), and paraformaldehyde (7 mg, 0.219 mmol) were added to a 25 mL single-necked flask, and the mixture was stirred at room temperature for 1 h. Then, NaBH3CN (14 mg, 0.219 mmol) was added, and the mixture was heated to 40 °C and stirred for 20 h. After the reaction was complete as detected by LC-MS, the mixture was concentrated, and the residue was purified by Flash chromatography (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column), lyophilized, and the compound (39 mg) was obtained.

[0518] LC-MS: m / z = 1018.4 [M+1] + .

[0519] Example 9 (1r,2R,3S)-N-(((2) 2 S,64 S,4S)-1 6 -Fluorine-1 2 -(2-((S)-1-methoxyethyl)-5-(4-((S)-4-methylmorpholin-2-carbonyl)piperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-1 1 -(2,2,2-trifluoroethyl)-1 1 H-8-Oza-6 2 6 3 Synthesis of 190-diaza-2(4,2)-morpholin-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptacycloundecane-4-yl)-2,3-dimethylcyclopropane-1-carboxamide:

[0520] Synthesis 190-1:

[0521] (R)-N-Boc-2-hydroxymethylmorpholine (25 g, 115 mmol), EA (400 mL), sodium bicarbonate (29 g, 345.2 mmol), and TEMPO (360 mg, 2.3 mmol) were added to a 1 L three-necked flask. After purging with argon, the mixture was cooled to -50 °C. A solution of TCCA (28.1 g, 120.8 mmol) / EA (125 mL) was added dropwise, and the mixture was then moved to 0 °C and reacted for 2 h. After the reaction was confirmed to be complete by LC-MS, saturated sodium thiosulfate (80 mL) was added dropwise to quench the reaction. The mixture was stirred at room temperature for 20 min, filtered, and the filter cake was washed with EA. The filtrate was separated, and the aqueous phase was extracted twice more with EA. The combined organic phases were washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product (24.7 g, Y: 99%).

[0522] LC-MS: m / z = 216.1 [M+1] + .

[0523] Synthesis 190-2:

[0524] 190-1 (24.7 g, 114.8 mmol), EA (400 mL), and methyl 2-(((benzyloxy)carbonyl)amino)-2-(dimethoxyphosphoryl)acetate (41.8 g, 126.28 mmol) were added to a 1 L single-necked flask. After argon protection, the mixture was cooled to -5 °C. TMG (33 g, 287 mmol) was added dropwise, and the reaction was maintained at this temperature for 1 h. After the reaction was confirmed to be complete by LC-MS, water (100 mL) was added dropwise to quench the reaction. The mixture was separated, and the aqueous phase was extracted again with EA. The organic phases were combined and washed with saturated citric acid, saturated sodium bicarbonate, and saturated sodium chloride, respectively. The mixture was concentrated and purified by column chromatography to obtain compound 190-2 (35.7 g, Y: 74%).

[0525] LC-MS: m / z = 421.2 [M+1] + .

[0526] Synthesize 190-3:

[0527] 190-2 (35.7 g, 84.9 mmol), MeOH (600 mL), and (S,S)-Et-DuPhos-Rh (4.3 g, 5.94 mmol) were added to a 1 L single-necked flask. After purging with hydrogen three times, the mixture was reacted at 45 °C for 6 h. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and purified by column chromatography to obtain compound 190-3 (30.1 g, Y: 84%, ee%: 94.5%).

[0528] LC-MS: m / z = 423.2 [M+1] + .

[0529] Sample name: 190-3

[0530] Instrument:Agilent 1260infinity 2

[0531] Column: CHIRALPAK AD-H 4.6*250mm,5um

[0532] Temperature: 30℃

[0533] Wave length: 214nm / 254nm

[0534] Phase A: Hex (0.1% FA)

[0535] Phase C: EtOH (0.1% FA)

[0536] Rt: 11.564min / 15.048min

[0537] Gradient:

[0538] Table 7

[0539] Synthesize 190-4:

[0540] Add 190-3 (30.1 g, 71.25 mmol) and DCM (300 mL) to a 500 mL single-necked flask, cool to 5 °C, add HCl / Dioxane (89 mL, 356 mmol, 4 M), and react at room temperature for 2 h. After the reaction is complete as detected by LC-MS, concentrate the reaction solution, neutralize the residue with saturated sodium bicarbonate solution in an ice bath, extract three times with DCM (200 mL * 3), combine the organic phases, wash with saturated sodium chloride, dry to anhydrous sodium sulfate, filter, and concentrate to obtain compound 190-4 (21.8 g, Y: 95%).

[0541] LC-MS: m / z = 323.2 [M+1] + .

[0542] Synthesize 190-5:

[0543] 190-4 (21.8 g, 67.63 mmol), IntB20 (43.13 g, 61.48 mmol), and Dioxane (600 mL) were added to a 1 L single-necked flask. Then, Cs2CO3 (60.1 g, 184.44 mmol), Ruphos (11.48 g, 24.59 mmol), chloro(2'-amino-1,1'-biphenyl-2-yl)palladium(II) dimer (1.71 g, 2.77 mmol), and Ruphos-Pd-G2 (2.15 g, 2.77 mmol) were added. After three purgings with argon, the mixture was reacted at 105 °C for 6 h. After the reaction was confirmed to be complete by LC-MS, the reaction mixture was filtered, the filter cake was washed with EA, the filtrate was concentrated, and the residue was purified by column chromatography to obtain compound 190-5 (43.5 g, Y: 75%).

[0544] LC-MS: m / z = 943.4 [M+1] + .

[0545] Synthesize 190-6:

[0546] Add 190-5 (43.5 g, 46.13 mmol) and THF (400 mL) / H2O (80 mL) to a 1 L single-necked flask, cool to 0-5 °C, add LiOH·H2O (9.68 g, 230.65 mmol), and react at 40 °C for 2 h. After the reaction is complete as detected by LC-MS, adjust the pH to 5-6 with saturated citric acid, concentrate, extract three times with DCM, combine the organic phases, wash with saturated sodium chloride, dry with anhydrous sodium sulfate, filter, and concentrate to obtain compound 190-6 (41.15 g, Y: 96%).

[0547] LC-MS: m / z = 929.4 [M+1] + .

[0548] Synthesize 190-7:

[0549] Add 190-6 (41.15 g, 44.29 mmol), IntA1 (16.86 g, 48.72 mmol), and ACN (400 mL) / DCM (80 mL) to a 1 L single-necked flask. Cool to 0-5 °C, add NMI (18.18 g, 221.45 mmol) and TCFH (18.64 g, 66.44 mmol), and react in an ice bath for 1 h. After the reaction is confirmed to be complete by LC-MS, concentrate the reaction solution, extract three times with DCM, combine the organic phases, wash with saturated sodium chloride, concentrate, and purify by column chromatography to obtain compound 190-7 (44 g, Y: 93%).

[0550] LC-MS: m / z = 1143.5 [M+1] + .

[0551] Synthesize 190-8:

[0552] Add 190-7 (44 g, 38.49 mmol) and THF (500 mL) / H2O (100 mL) to a 1 L single-necked flask, cool to 0-5 °C, add LiOH·H2O (2.59 g, 61.85 mmol), and react in an ice bath for 1 h. After the reaction is complete as determined by LC-MS, adjust the pH to 5-6 with saturated citric acid, concentrate, extract three times with DCM, combine the organic phases, wash with saturated sodium chloride, dry with anhydrous sodium sulfate, filter, and concentrate to obtain compound 190-8 (43.4 g, Y: 100%).

[0553] LC-MS: m / z = 1053.5 [M+1] + .

[0554] Synthesize 190-9:

[0555] DIPEA (16 g, 123.6 mmol), DMAP (2.52 g, 20.6 mmol), HOBt (11.1 g, 82.4 mmol), EDCI (23.7 g, 123.6 mmol), and DCM (1.3 L) were added to a 2 L single-necked flask. The mixture was stirred at room temperature, and a solution of 190-8 (43.4 g, 41.2 mmol) / DCM (400 mL) was slowly added dropwise. After the addition was complete, the mixture was allowed to react overnight at room temperature. After LC-MS analysis to confirm the completeness of the reaction, water was added, and the mixture was extracted twice with DCM. The organic phases were combined, washed with saturated sodium chloride, and purified by column chromatography to obtain compound 190-9 (21.3 g, Y: 50%, containing isomers). The isomers were resolved by prep-HPLC according to method 64-5 to obtain a chiral pure product (13.3 g, Y: 62.4%).

[0556] LC-MS: m / z = 1135.5 [M+1] +.

[0557] Synthesis of 190-10:

[0558] 190-9 (13.3 g, 11.71 mmol) and MeOH (200 mL) were added to a 500 mL single-necked flask, followed by the addition of 20% Pd(OH)2 / C (2.6 g). After hydrogen purging, the mixture was reacted at room temperature for 20 h. After the reaction was confirmed to be complete by LC-MS, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a white solid product (10.5 g, Y: 99%).

[0559] LC-MS: m / z = 901.5 [M+1] + .

[0560] Synthesis of 190-11:

[0561] 190-10 (1.18 g, 1.31 mmol) and DCM (60 mL) were added to a 250 mL single-necked flask. After argon protection, the mixture was cooled to 0-5 °C, and then NMM (397 mg, 3.93 mmol), (1r,2R,3S)-2,3-dimethylcyclopropane-1-carboxylic acid (194 mg, 1.70 mmol), HOBt (35 mg, 0.262 mmol), and EDCI (452 ​​mg, 2.36 mmol) were added sequentially. The mixture was allowed to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated, purified by flash filtration, and lyophilized to obtain the compound (1.16 g, Y: 88.8%).

[0562] LC-MS: m / z = 997.5 [M+1] + .

[0563] Synthesis of 190-12:

[0564] Add 190-11 (1.01 g, 1.01 mmol) and DCM (20 mL) to a 100 mL single-necked flask, stir at room temperature, then add TFA (5 mL) to the system and react at room temperature for 1 h. After the reaction is complete as detected by LC-MS, concentrate the reaction solution, add DCM, adjust the pH to 7-8 with saturated sodium bicarbonate solution, extract three times with DCM, combine the organic phases, concentrate, and purify the residue by Flash purification (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column), lyophilize to obtain the compound (900 mg, Y: 99.3%).

[0565] LC-MS: m / z = 897.5 [M+1] + .

[0566] Synthesis of 190-13:

[0567] 190-11 (61 mg, 0.0684 mmol) and DCM (5 mL) were added to a 25 mL single-necked flask. After argon protection, the mixture was cooled to 0-5 °C, and NMM (21 mg, 0.2052 mmol), (S)-4-(tert-butyloxycarbonyl)morpholine-2-carboxylic acid (21 mg, 0.0889 mmol), HOBt (2 mg, 0.0137 mmol), and EDCI (24 mg, 0.123 mmol) were added sequentially. The mixture was allowed to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, the reaction solution was concentrated and then purified by Flash (0.1% TFA aqueous solution / acetonitrile, through a reversed-phase column), and lyophilized to obtain compound 190-13 (58 mg, Y: 76.4%).

[0568] LC-MS: m / z = 1110.5 [M+1] + .

[0569] Synthesis of 190-14:

[0570] Add 190-13 (58 mg, 0.052 mmol) and DCM (2 mL) to a 50 mL single-necked flask, stir at room temperature, then add TFA (1 mL) to the system and react at room temperature for 1 h. After the reaction is complete as detected by LC-MS, concentrate the reaction solution, add DCM, adjust the pH to 7-8 with saturated sodium bicarbonate solution, extract three times with DCM, combine the organic phases, concentrate, and purify the residue by Flash purification (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column), lyophilize, and obtain the compound (50 mg).

[0571] LC-MS: m / z = 10¹⁰.⁵ [M+1] + .

[0572] Synthesis of 190:

[0573] 190-14 (40 mg, 0.0396 mmol), MeOH (3 mL), AcOH (1 drop), and paraformaldehyde (7 mg, 0.227 mmol) were added to a 25 mL single-necked flask, and the mixture was stirred at room temperature for 1 h. Then, NaBH3CN (9 mg, 0.136 mmol) was added, and the mixture was heated to 40 °C and stirred for 20 h. After the reaction was complete as detected by LC-MS, the mixture was concentrated, and the residue was purified by Flash chromatography (0.1% ammonium bicarbonate aqueous solution / acetonitrile, through a reversed-phase column), lyophilized, and the compound was obtained (32 mg, Y: 78.9%).

[0574] LC-MS: m / z = 1024.5 [M+1] + .

[0575] Example 10N-((6) 4 S,4S,Z)-12 -(5-(4-(2-hydroxy-2-(pyridin-3-yl)acetyl)piperazin-1-yl)-2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-1 1 -(2,2,2-trifluoroethyl)-1 1 H-8-Oza-6 2 6 3 -diaza-2(4,2)-thiazo-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptan-1 / 2-undecane-4-yl)bicyclo[4.1.0]heptan-7-carboxamide (compound 206) and N-((6 4 S,4S,Z)-1 2 -(2-((S)-1-methoxyethyl)-5-(4-(2-oxo-2-(pyridin-3-yl)acetyl)piperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-1 1 -(2,2,2-trifluoroethyl)-1 1 H-8-Oza-6 2 6 3 Synthesis of 2-diaza-2(4,2)-thiazo-1(5,3)-indole-6(2,4)-bicyclo[3.1.1]heptanecycloundecane-4-yl)bicyclo[4.1.0]heptane-7-carboxamide (compound 207):

[0576] Synthesis of 206-1:

[0577] Add ethyl 2-oxo-2-(pyridin-3-yl)acetate (100 mg, 0.558 mmol), EtOH (1 ml), THF (1 ml), water (0.5 ml), and LiOH·H₂O (117 mg, 2.79 mmol) to a 25 mL single-necked flask. Stir the mixture at room temperature for 3 h. After the reaction is complete as detected by LC-MS, adjust the pH of the mixture to 4–5 with dilute hydrochloric acid, then purify it using a flash filter (pure water / ACN), and freeze-dry to obtain a white solid (240 mg, Y: >100%).

[0578] LC-MS: m / z = 150.0 [M-1] - .

[0579] Synthesis of 207:

[0580] Add 64-8 (40 mg, 0.044 mmol) and DCM (2 mL) to a 25 mL single-necked flask. After argon protection, cool to 0-5 °C, then add NMM (45 mg, 0.44 mmol), 202-1 (95 mg, containing salt, 0.22 mmol), HOBt (2 mg, 0.013 mmol), and EDCI (23 mg, 0.120 mmol). Allow the mixture to react overnight in an ice bath. After the reaction was confirmed to be complete by LC-MS, concentrate the reaction solution, then purify it using a Flash filter (0.1% TFA aqueous solution / acetonitrile, through a reversed-phase column), and freeze-dry to obtain compound 202-2 (31 mg, Y: 68%).

[0581] LC-MS: m / z = 1036.4 [M+1] + .

[0582] Synthesis of 206:

[0583] 207 (34 mg, 0.033 mmol) and THF (1 mL) were added to a 25 mL single-necked flask. NaBH4 (1 mg, 0.026 mmol) was then added to the mixture at room temperature, and the mixture was stirred for 1 h. After LC-MS analysis showed that the starting material had essentially disappeared, the mixture was quenched with water (1 mL), concentrated, and the residue was purified by flash purification (0.1% formic acid aqueous solution / acetonitrile, through a reversed-phase column). The residue was then lyophilized to obtain the compound (10 mg).

[0584] LC-MS: m / z = 1038.4 [M+1] + .

[0585] Using different raw materials and similar synthesis methods as in Examples 1-10, the target compounds in Table 8 were obtained.

[0586] Table 8

[0587] The NMR data for some of the compounds in this patent are listed in Table 9 below:

[0588] Table 9

[0589] Example 1: Detection of pERK and ERK protein levels in Capan-1 cells using compounds - ELISA

[0590] Capan-1 cells were seeded in each well of a 96-well plate. After one day of growth, the test compound (5 nM) was added. After 3 hours of treatment with the compound, the cells were lysed. The pERK level in the lysate was measured by ELISA and compared with the DMSO group. The percentage of pERK activity inhibited by the compound was calculated. The results are shown in Table 10 below.

[0591] Table 10. Inhibitory activity of the compounds of the present invention against intracellular pERK levels in Capan-1 cells.

[0592] + indicates an inhibition rate of 50% or less.

[0593] ++ indicates an inhibition rate of 50% to 90%.

[0594] +++ indicates an inhibition rate greater than 90%.

[0595] Example 2: Detection of pERK and ERK protein levels in AsPC-1 cells using compounds - ELISA

[0596] AsPC-1 cells were seeded at 1000 cells per well in a 96-well plate. After one day of growth, the test compound (5 nM) was added. After 3 hours of compound treatment, the cells were fixed and the pERK level in the cells was measured using In-Cell Western blotting. The results were compared with the DMSO group, and the percentage of pERK activity inhibited by the compound was calculated.

[0597] Table 11. Inhibitory activity of the compounds of the present invention against intracellular pERK levels in AsPC-1 cells.

[0598] + indicates an inhibition rate of 50% or less.

[0599] ++ indicates an inhibition rate of 50% to 90%.

[0600] +++ indicates an inhibition rate greater than 90%.

[0601] Biological Example 3: Antiproliferative activity of the compound against AsPC-1 / Capan-1 / H358 cells, etc.

[0602] AsPC-1 / Capan-1 / H358 cells were seeded in 384-well plates. After one day of growth, serially diluted compounds (maximum 100 nM, 5-fold dilution, for a total of five doses) were added. Five days after adding the compounds, Cell Titer Glow (Promega, G9681) was added to evaluate cell growth, and IC50 was calculated. 50 The values ​​are shown in Tables 12 and 14 below.

[0603] Table 12. Antiproliferative activity of the compounds of the present invention against AsPC-1 / Capan-1 cells

[0604] + indicates the compound's IC. 50 Greater than 50 nM;

[0605] ++ indicates the IC of the compound. 50 The range is 5 to 50 nM;

[0606] +++ indicates the IC of the compound. 50 Less than 5 nM;

[0607] ND indicates that it has not been tested.

[0608] *The control compound is RMC6236, synthesized according to compound A122 in patent WO2022060836 (page 70, Table 1a). Control compound 2 is compound 6A in patent WO2024 / 067857 (page 79).

[0609] Biological Example 4: Antiproliferative Activity of Compound on Miapaca2 Cells

[0610] Miapaca2 cells were seeded in ultra-low adsorption 96-well plates (corning, 7007). After one day of growth, serially diluted compounds (maximum 50 nM, 5-fold dilution, for a total of five doses) were added. Five days after adding the compounds, Cell Titer Glow (Promega, G9681) was added to evaluate cell growth, and IC50 was calculated. 50 The values ​​are shown in Table 13 below.

[0611] Table 13. Antiproliferative activity of the compounds of the present invention against Miapaca2 cells

[0612] + indicates the compound's IC. 50 Greater than 50 nM;

[0613] ++ indicates the IC of the compound. 50 The range is 5 to 50 nM;

[0614] +++ indicates the IC of the compound. 50 Less than 5 nM;

[0615] ND indicates that it has not been tested.

[0616] Biological Example 5: Antiproliferative Activity of Compounds on H1975 / H358 Cells

[0617] H1975 cells were seeded in ultra-low adsorption 96-well plates (corning, 7007). After one day of growth, serially diluted compounds were added (to evaluate cell growth). Five days after adding the compounds, Cell Titer Glow (Promega, G9681) was added to evaluate the growth of the spheres, and the IC50 was calculated. 50 The values ​​are shown in Table 14 below.

[0618] Table 14. Antiproliferative activity of the compounds of the present invention against H1975 / H358 cells

[0619] + indicates the compound's IC. 50 Greater than 50 nM;

[0620] ++ indicates the IC of the compound. 50 The range is 5 to 50 nM;

[0621] +++ indicates the IC of the compound. 50 Less than 5 nM;

[0622] ND indicates that it has not been tested.

[0623] Example 6: Pharmacokinetic Evaluation in Mice

[0624] The compound was administered via intravenous injection and oral gavage. The intravenous dose was 2 mg / kg, and the oral dose was 10 mg / kg. Fifteen female ICR mice were used in each group. Three non-contiguous time points were collected from each mouse, with three mice at each time point. Sampling time points were before administration, and 5 min, 15 min, 30 min, 1 h, 3 h, 5 h, 8 h, 12 h, and 24 h after administration. Approximately 80 μL of blood was collected from the orbital sinus at each time point after administration. All whole blood samples were collected in tubes containing EDTA K2, centrifuged at 4 °C (1500 rpm) for 10 min, and the plasma was separated and stored at -80 °C for analysis. The concentration of the compound in plasma was determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS), and the corresponding pharmacokinetic parameters were calculated based on the plasma concentration-time curve.

[0625] Table 15. In vivo pharmacokinetic evaluation results of the compounds

[0626] # indicates that the oral dosage is 1 mg / kg and the injectable dosage is 0.5 mg / kg;

[0627] ## indicates that the oral dosage is 5 mg / kg and the injectable dosage is 2 mg / kg.

[0628] Biological Example 7: Pharmacokinetic Evaluation in Rats

[0629] The compound was administered via intravenous injection and oral gavage. The intravenous dose was 1 mg / kg, and the oral dose was 5 mg / kg. Three male SD rats were used in each group. Blood samples were collected from the jugular vein at 5 min, 15 min, 30 min, 1 h, 3 h, 5 h, 8 h, 12 h, and 24 h after administration. All whole blood samples were collected in tubes containing EDTA K2, centrifuged at 4 °C (1500 rpm) for 10 min, and the plasma was separated and stored at -80 °C for analysis. The concentration of the compound in the plasma was determined by liquid chromatography-tandem mass spectrometry, and the corresponding pharmacokinetic parameters were determined based on the plasma concentration-time curve.

[0630] Table 16. In vivo pharmacokinetic evaluation results of the compounds

[0631] Biological Example 8: Evaluation of Antitumor Activity in Mice

[0632] Miapaca2 / Capan-1 / AsPC-1 tumor cells were routinely cultured in 1640 medium containing 10% fetal bovine serum at 37°C in a 5% CO2 incubator. After passage, cells were collected when the desired cell count was reached. 1×10⁶ cells were then cultured.7 One MiaPACA-2 / Capan-1 / AsPC-1 cell was injected into the left side of each nude mouse, and the tumor was allowed to grow to 150 mm. 3 Afterwards, the animals were randomly divided into groups to begin drug administration. Tumor volume and mouse weight were measured every Tuesday and Thursday. Nude mice were sacrificed on day 21 of drug administration, tumors were collected and weighed, and tumor inhibition capacity and weight changes were calculated.

[0633] Table 17 In vivo efficacy experiments of AsPC

[0634] While specific embodiments of the present invention have been described above, those skilled in the art should understand that these are merely illustrative examples, and various changes or modifications can be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.

Claims

1. A compound of Formula (1) or each isomer, each crystalline form, pharmaceutically acceptable salt, hydrate or solvate thereof: ###0001### Formula (1) ​ in the general formula (1): Ring D is (C5-C14)heterocycloalkyl, (C6-C14)aryl or (5-14 membered)heteroaryl; X1and X2are each independently N or CR d ; X3is C-R 5 or N-R 5 X4is C or N, and X3and X4are not simultaneously N; represents a single or double bond, and when X3or X4is N, the bond to it is not present is represented as a single bond; R 1 is -OR a , -NR a R b , (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl, wherein the (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R d ; R 2 Each can be independently represented as -H, -D, halogen, hydroxyl, amino, cyano, nitro, or -OR. a -NR a R b -C(O)R a -CO2R a -S(O) p R a -S(O) p NR a R b -C(O)NR a R b -C(=NR) a )-NR b R c -NR a C(O)R b -NR a C(O)NR b R c -NR a CO2R b -NR a S(O) p NR b R c -NR a S(O) p R b -P(O)R a R b -P(S)R a R b -N(=S(O)R a R b ), -BR a R b (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace; R 3 -H, -D, halogen, hydroxyl, amino, cyano, nitro, -OR a -NR a R b -C(O)R a -CO2R a -S(O) p R a -S(O) p NR a R b -C(O)NR a R b -C(=NR) a )-NR b R c -NR a C(O)R b -NR a C(O)NR b R c -NR a CO2R b -NR a S(O) p NR b R c -NR a S(O) p R b -P(O)R a R b -P(S)R a R b -N(=S(O)R a R b ), -BR a R b (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace; R 5 -H, (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl, wherein the (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R d substituents; R 6 -H, (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl, wherein the (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R d substituents; R 7 (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R d substituents; Or R 5 With R 7 The atoms attached to the alkyl group together constitute a (7-16 member) heterocyclic alkyl group, wherein each heterocyclic alkyl group may be independently optionally bound by 1, 2, 3 or 4 R groups. d replace; R 4 -H, -D, halogen, hydroxyl, amino, cyano, nitro, -OR a -NR a R b -C(O)R a -CO2R a -S(O) p R a -S(O) p NR a R b -C(O)NR a R b -C(=NR) a )-NR b R c -NR a C(O)R b -NR a C(O)NR b R c -NR a CO2R b -NR a S(O) p NR b R c -NR a S(O) p R b -P(O)R a R b -P(S)R a R b -N(=S(O)R a R b ), -BR a R b (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocyclic alkyl, (C6-C14)aryl, or (5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace; R a , R b , and R c are each independently H, (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-Ci4)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-Ci4)aryl, (5-14 membered)heteroaryl, -(Ci-C8)alkylene-(C3-Ci4)cycloalkyl, -(Ci-C8)alkylene-(3-14 membered)heterocycloalkyl, -(Ci-C8)alkylene-(C6-Ci4)aryl, or -(Ci-C8)alkylene-(5-14 membered)heteroaryl, wherein the (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-Ci4)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-Ci4)aryl, (5-14 membered)heteroaryl, -(Ci-C8)alkylene-(C3-Ci4) cycloalkyl, -(Ci-C8)alkylene-(3-14 membered)haterocycloalkyl, -(Ci-C8)alkylene-(C6-Ci4) e aryl, -(Ci-C8)alkylene-(5-14 membered)heteroaryl can each independently be optionally substituted with 1, 2, 3, or 4 R or R a and R b , R b and R c or R a and R c together with the atom(s) to which they are attached form a (3-12 membered)heterocycloalkyl group, wherein said (3-12 membered)heterocycloalkyl group is optionally substituted with 1, 2, 3 or 4 R e groups; R d Each can be independently represented as -H, -D, halogen, hydroxyl, amino, cyano, nitro, or -OR. e -NR e R f -NR e NR f R g -NR e OR f -OR e NR f -C(O)R e -CO2R e -S(O) p R e -S(O) p NR e R f -C(O)NR e R f -C(=NR) e )-NR f R g -NR e C(O)R f -NR e C(O)NR f R g -NR e CO2R f -NR e S(O) p NR f R g -NR e S(O) p R f -P(O)R e R f -P(S)R e R f -N(=S(O)R e R f (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, (5-14 membered)heteroaryl, -(C2-C8)alkynyl-(C1-C8)alkylene, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14 membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, or -(C1-C8)alkylene-(5-14 membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1- C8)haloalkyl, (C2-C8)alkenyl, (C1-C8)alkynyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl, (3-14 membered heterocycloalkyl, (C6-C14)aryl, (5-14 member)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, e substituted; or when 2 R d when attached to the same atom, can form an oxo group or a (C3-C8)cycloalkyl or (3-8 membered)heterocycloalkyl group with the atom to which they are attached, each of which (C3-C8)cycloalkyl, (3-8 membered)heterocycloalkyl can be independently optionally substituted with 1, 2, 3, or 4 R e substituents; R e each independently -H, -D, halogen, hydroxyl, amino, cyano, nitro, -OR f , -NR f R g , -NR f NR g R h , -NR f OR g , -OR f NR g , -C(O)R f , -CO2R f , -S(O) p R f , -S(O) p NR f R g , -C(O)NR f R g , -C(=NR f )-NR f R g , -NR h C(O)R f , -NR g C(O)NR f R g , -NR h CO2R f , -NR g S(O) f NR p R g , -NR h S(O) f R p , -NR g , (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, (5-14 membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14 membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, or -(C1-C8)alkylene-(5-14 membered)heteroaryl, which (C1-C8)alkyl, (C1-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, ( C2-C8)alkynyl, (C3-C14)cycloalkyl, R f , R g , and R h are each independently H, (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-Ci4)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-Ci4)aryl, (5-14 membered)heteroaryl, -(Ci-C8)alkylene-(C3-Ci4)cycloalkyl, -(Ci-C8)alkylene-(3-14 membered)heterocycloalkyl, -(Ci-C8)alkylene-(C6-Ci4)aryl, or -(Ci-C8)alkylene-(5-14 membered)heteroaryl, which (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-Cg)haloalkyl, (C2-C8)alkenyl, (C2- C8)alkynyl, (C3-Ci4)cycloalkyl, (S-14 membered)heterocycloalkyl, (C6-Ci4Jaryl, (5-14 membered)heteroaryl, -(Ci-C8) alkylene-(C3-Ci4)cycloalkyl, -(Ci-C8)alky lene-(3-14 membered)heterocycloalkyl, -(Ci-C8)a lky lene-(C6-Ci4)aryl, -(Ci-C8)alkylene-(5-14 membered)heteroaryl can each independently be optionally substituted with 1, 2, 3, or 4 R; each R is independently -H, -D, halogen, hydroxyl, amino, cyano, nitro, -NH-NH2, -ONH2, -NHOH, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, (5-14 membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14 membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl or -(C1-C8)alkylene-(5-14 membered)heteroaryl; n, p are each independently an integer of 0, 1, 2, 3 or 4.

2. The compound according to claim 1, wherein R is (C3-C10)cycloalkyl or (3-10 membered)heterocycloalkyl, each independently optionally substituted with 1, 2, 3 or 4 H, D, methyl, halomethyl or deuterated methyl, or each isomer, crystalline form, pharmaceutically acceptable salt, hydrate or solvate thereof. 1 2. The compound according to claim 1, wherein R is (C3-C10)cycloalkyl or (3-10 membered)heterocycloalkyl, each independently optionally substituted with 1, 2, 3 or 4 H, D, methyl, halomethyl or deuterated methyl, or each isomer, crystalline form, pharmaceutically acceptable salt, hydrate or solvate thereof.

3. The compound according to claim 1 or 2, wherein X1 and X2 are each independently N or CR in the general formula (1), R is -H, -D or halogen; X1 is preferably CH, CF or N, and X2 is preferably CH; X3 is C-R or N-R, and X4 is C or N, and X3 and X4 are not simultaneously N; or an isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. d d 5 5 , or an isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.​​​ 4. The compound according to any one of claims 1 to 3, wherein R 3 is -H, -D, halogen, (Ci-C3)alkyl, (Ci-C3)alkoxy, (Ci-C3)haloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl or (C3-C6)cycloalkyl; R 3 is preferably -H, -D, halogen, methyl or -CF3; or a respective isomer, a respective crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof.

5. The compound according to any one of claims 1 to 4, wherein the structural unit of the general formula (1) is ###0002### or a respective isomer, a respective crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. is is preferably 6. The compound according to any one of claims 1 to 5, wherein R in the general formula (1) is -H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (3-10 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl, wherein each of said (C1-C6)alkyl, (C1-C6)alkoxy, (Cl- C6)haloalkyl, (C2-C6)alkenyl, (C -C6)alkynyl, (C3-C10)cycloalkyl, (3-lO membered)heterocycloalkyl, (C6-C14)aryl, and (5-14 membered)heteroaryl is optionally substituted with 1, 2, 3, or 4 R independently; or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate, or a solvate thereof. 5 (C2-C4)alkyl, (C2-C4)alkoxy, (C2-C4)haloalkyl, (C3-C5)cycloalkyl, or (3-5 membered)heterocycloalkyl, wherein each of said (C2-C4)alkyl, (C2-C4)alkoxy, (C2- C4)haloalkyl, (C3-C5)cycloalkyl, and (3-5 membered)heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 R independently; R is -H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C10)cycloalkyl, (3-10 membered) d heterocycloalkyl, (C6-C14)aryl, or (5-l4 membered)heteroaryl, wherein each of said (C1-C6)alkyi, (C1-C6)haloalkyl, (C3-C10)cycioalkyl, (3-lO membered)heterocycloalkyl, (Ce-C14)aryl, and (5-l4 membered)heteroaryl is optionally substituted with 1, 2, 3, 5 or 4 R independently; R is -H, (C1-C6)alkyl, or (C1-C6)haloalkyl; and R is -H, (C1-C6)alkyl, (C1-C6)aikoxy, (C1-C6)haloalkyl, (C2-C6)alkynyl, (C3-C10)cycioalkyl, (3-lO membered) d heterocycloalkyl, (C6-C14)aryl, or (S-l4 membered)heteroaryl, wherein each of said (C1-C6)aikyl, (C1-C6)alkoxy, (C1-C6)haloaiikyl, (C2-C6)alkynyl, (C3-C10)cyciolkyl, (3-lO membered)heterocycloalkyl, (Cg-C14)aryl, and (5-l4 membered)heteroaryl is optionally 5 substituted with 1, 2, 3, or 4 R independently; R is - H, (C1-C6)alkyl, or (C1-C6)haloaiikyl; and R is -H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)aiikynyl, (C3-C10)cycloalkyl, (3-lO member 7. The compound according to any one of claims 1 to 6, wherein R 2 is -H, -D, halogen, hydroxyl, amino, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C4)alkenyl, (C2-C4)alkynyl or (C3-C6)cycloalkyl; R 2 is preferably -H, -D, halogen, methyl, hydroxyl or amino, or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof.

8. The compound according to any one of claims 1 to 7, wherein, in the general formula (1), ring D is (C5-C6)heterocycloalkyl, phenyl or (5-6 membered)heteroaryl; ring D is preferably ring D is more preferably wherein * indicates the attachment to the aromatic ring.

9. The compound or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as described in any one of claims 1-8, wherein in the general formula (1), R 4 For -OR a -NR a R b P(O)R a R b -P(S)R a R b -N(=S(O)R a R b (C2-C4) ynyl, (C3-C10) cycloalkyl, (3-10) heterocycloalkyl, phenyl, or (5-10) heteroaryl, wherein the (C2-C4) ynyl, (C3-C10) cycloalkyl, (3-10) heterocycloalkyl, phenyl, or (5-10) heteroaryl can each be independently and optionally surrounded by 1, 2, 3, or 4 R's. d replace.

10. The compound of claim 9 or any of its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 4 It is (C2-C3) ynyl, (5-10) heterocyclic alkyl, phenyl, or (5-7) heteroaryl, wherein the (C2-C3) ynyl, (5-10) heterocyclic alkyl, phenyl, or (5-7) heteroaryl can each be independently optionally surrounded by 1, 2, 3, or 4 R groups. d replace.

11. The compound according to claim 10, wherein in the general formula (1), R is propynyl, 6-membered heterocycloalkyl, phenyl or 5-membered heteroaryl, wherein the propynyl, 6-membered heterocycloalkyl, phenyl, 5-membered heteroaryl can each independently be optionally substituted with -NR, -C(O)R, (C1-C3)alkyl or (3-6 membered)heterocycloalkyl, wherein the (C1-C3)alkyl or (3-6 membered)heterocycloalkyl can each independently be optionally substituted with 1, 2, 3 or 4 R, or an isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof. 4 R e R f e e R​​ 12. The compound or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as described in any one of claims 1-11, wherein in the general formula (1), R a R b and R c Each of these components is independently H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (3-10-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C6)alkylene-(C3-C10)cycloalkyl, -(C1-C6)alkylene-(3-10-membered)heterocyclic alkyl, -(C1-C6)alkylene-(C6-C14)aryl, or -(C1-C6)alkylene-(5-14-membered)heteroaryl, wherein (C 1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C10)cycloalkyl, (3-10-membered)heterocyclic alkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C6)alkylene-(C3-C10)cycloalkyl, -(C1-C6)alkylene-(3-10-membered)heterocyclic alkyl, -(C1-C6)alkylene-(C6-C14)aryl, -(C1-C6)alkylene-(5-14-membered)heteroaryl can each be independently and optionally surrounded by 1, 2, 3 or 4 Rs. e Replace; or R a and R b R b and R c Or R a and R c Together with one or more atoms to which they are attached, they form (3-12-membered) heterocyclic alkyl groups, wherein the (3-12-membered) heterocyclic alkyl groups may optionally be composed of 1, 2, 3 or 4 R atoms. e Replace; R a R b Preferably, the alkyl group is H, D, (C1-C4)alkyl, (C1-C4)alkoxy, or (3-10)heterocyclic alkyl, wherein the (C1-C4)alkyl, (C1-C4)alkoxy, or (3-10)heterocyclic alkyl group may each be independently and optionally surrounded by 1, 2, 3, or 4 R groups. e Replace; or R a and R b Together with one or more atoms to which they are attached, they form (3-12-membered) heterocyclic alkyl groups, wherein the (3-12-membered) heterocyclic alkyl groups may optionally be composed of 1, 2, 3 or 4 R atoms. e replace.

13. The compound according to any one of claims 1 to 12, wherein R in the general formula (1) is -H, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R, or an isomer, crystal, pharmaceutically acceptable salt, hydrate, or solvate thereof. 6 (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R d (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R 6 (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, or (5-14 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R 6 (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8) 14. The compound according to any one of claims 1 to 13, wherein R in the general formula (1) is (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-Ci4)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-Ci4)aryl, or (5-14 membered)heteroaryl, each of which is independently optionally substituted with 1, 2, 3, or 4 R, or an isomer, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof. 7 (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-Ci4)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-Ci4)aryl, or (5-14 membered)heteroaryl, each of which is independently optionally substituted with 1, 2, 3, or 4 R. d (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-Ci4)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-Ci4)aryl, or (5-14 membered)heteroaryl, each of which is independently optionally substituted with 1, 2, 3, or 4 R. 7 (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-Ci4)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-Ci4)aryl, or (5-14 membered)heteroaryl, each of which is independently optionally substituted with 1, 2, 3, or 4 R. d (Ci-C8)alkyl, (Ci-C8)alkoxy, (Ci-Cs)haloalkyl, (C2-C8)alkenyl, (C2-Cs)alkynyl, (C3-Ci4)cycloalkyl, (3-Ci4)heterocycloalkyl, (C6-Ci4)aryl, or 15. The compound according to any one of claims 1 to 13, wherein, in the general formula (1), R 5 and the atom to which they are attached together form a (7-16 membered) heterocycloalkyl group, each of which is optionally substituted independently with 1, 2, 3 or 4 R 7 groups; or a stereoisomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. d and the atom to which they are attached together form a (7-16 membered) heterocycloalkyl group, each of which is optionally substituted independently with 1, 2, 3 or 4 R 5 groups; or a stereoisomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. 7 and the atom to which they are attached together form a (8-12 membered) heterocycloalkyl group, each of which is optionally substituted independently with 1, 2, 3 or 4 R d groups.

16. The compound or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as described in any one of claims 1-15, wherein in the general formula (1), R e Each can be independently represented as -H, -D, halogen, hydroxyl, amino, cyano, nitro, or -OR. f -NR f R g -NR f NR g R h -NR f OR g -OR f NR g -C(O)R f -CO2R f -S(O) p R f -S(O) p NR f R g -C(O)NR f R g -C(=NR) f )-NR f R h -NR f C(O)R g -NR f C(O)NR g R h -NR f CO2R g -NR f S(O) p NR g R h -NR f S(O) p R g , (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (4-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6 membered)heterocycloalkyl, -(C1-C2)alkylene-phenyl, or -(C1-C2)alkylene-(5-6 membered)heteroaryl, which (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (4-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6 membered)heterocycloalkyl, (C1-C2)alkylene-phenyl, -(C1-C2)alkylene-(5-6 membered)heteroaryl can each be independently optionally substituted with 1, 2, 3, or 4 R.

17. The compound of any one of claims 1-16, or each isomer, each crystalline form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R f , R g and R h are each independently H, (Ci-C3)alkyl, (Ci-C3)alkoxy, (Ci-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (3-6 membered)heterocycloalkyl, (C6-Cio)aryl, (5-6 membered)heteroaryl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, -(Ci-C2)alkylene-(3-6 membered)heterocycloalkyl, -(Ci-C2)alkylene-(C6-Cio)aryl, or -(Ci-C2)alkylene-(5-6 membered)heteroaryl, which (Ci-C3)alkyl, (Ci-C3)alkoxy, (Ci-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (3-6 membered)heterocycloalkyl, (C6-Cio)aryl, (5-6 membered)heteroaryl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, -(Ci-C2)alkylene-(3-6 membered)heterocycloalkyl, -(Ci-C2)alkylene-(C6-Cio)aryl, -(Ci-C2)alkylene-(5-6 membered)heteroaryl can each independently be optionally substituted with 1, 2, 3 or 4 R.

18. The compound of any one of claims 1-17, or each isomer, each crystalline form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), each R is independently -H, -D, halogen, hydroxyl, amino, cy ano, nitro, -NH-NH2, -ONH2, -NHOH, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)haloalkyl, (C2-C3)alkenyl, (C2-C3)alkynyl, (C3-C6)cycloalkyl, (3-6 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl, -(C1-C2)alkylene-(C3-C6)cycloalkyl, -(C1-C2)alkylene-(3-6 membered)heterocycloalkyl, -(C1-C2)alkylene-(C6-C10)aryl or -(C1-C2)alkylene-(5-6 membered)heteroaryl.

19. The compound of any one of claims 1-18, or each isomer, each crystalline form, pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the compound has one of the following structures:

20. A pharmaceutical composition comprising, containing a pharmaceutically acceptable excipient or carrier, and the compound of any one of claims 1-19, or each isomer, each crystalline form, pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient.

21. Use of the compound of any one of claims 1-19, or each isomer, each crystall ine form, pharmaceutically acceptable salt, hydrate, or solvate thereof, or the pharmaceutical composition of claim 20, for the manufacture of a medicament for the treatment, modulation and / or prevention of a disease associated with RAS inhibitors.

22. The use of claim 21, wherein the disease is cancer, the cancer is a hematological cancer or a solid tumor, preferably lung cancer, pancreatic cancer, colon cancer, gastric cancer, breast cancer, uterine cancer, blood cancer, lymphatic cancer, prostate cancer, liver cancer, cervical cancer, neuroblastoma, melanoma or intracranial tumor.